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Abstract

Postpartum depression (PPD) is a serious and potentially debilitating disorder that
frequently goes undetected due to stigma and a lack of understanding about its course and
etiology. The factor of particular interest to this study concerns the relationship between
discontinuation of anti-depressant medication in pregnancy and the development of PPD.
The study examined how the variables of pregnancy mood, child care stress, emotional
support, instrumental support, marital satisfaction, history of depression, baby
temperament, birth experience, and medication status affect symptoms of postpartum
depression (PPD) in a sample of 202 patients at the six-week postpartum check-up. In
addition to a demographic and mood questionnaire, the Postpartum Depression Screening
Scale (PDSS) was used to measure symptoms of postpartum depression. Prenatal
depression, child care stress, history of depression, baby temperament, and birth
experience correlated significantly with PPD. Significant inverse correlations were found
between PPD and emotional support, instrumental support, marital satisfaction, and
medication status. Hierarchical multiple regression indicated that pregnancy mood, child
care stress, emotional support, and marital satisfaction predicted a significant amount of
the variance in postpartum depression scores.
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Chapter 1
Introduction
Postpartum Depression (PPD), also know as postnatal depression, is a serious and
often under-reported disorder which affects a significant number of women in this
country and around the world. The National Mental Health Association ([NMHA], 2003)
estimates that PPD occurs in roughly 10 to 20 percent of new mothers. Beck (2002)
conceptualized PPD as “a thief that robs mothers of the love and happiness they expected
to feel toward their newborn babies” (p.453). PPD can also be conceptualized on a
continuum ranging from the mild and often spontaneously remitting symptoms of the
blues to the most severe symptom profile associated with a postpartum psychosis. The
current study focuses primarily on the middle range symptom picture which is analogous
to a major depressive disorder. One of the most salient risk factors associated with an
onset of PPD is a history of a depression; approximately 12 million women in the United
States experience a clinical depression each year, most frequently during the childbearing
years (ages 25-44) (National Institute of Mental Health [NIMH], 1999). Women
experience depression at a rate that is two times higher than men (NMHA, 2003).
Psychotherapy continues to be an effective treatment for depression, either as a
substitute for or in conjunction with medication. With the proliferation of managed care
plans, many individuals must first consult their primary care doctors with symptoms of
depression. The past two decades have also seen a boom in newer anti-depressant
medications like selective serotonin reuptake inhibitors (SSRIs), which have more
favorable side effect profiles and lower toxicity associated with overdose (Richelson,
1994) in comparison to older anti-depressants. The combination of managed care and
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medication proliferation seems to have resulted in a trend whereby anti-depressant
medication is becoming standard treatment for depression. SSRIs relieve symptoms by
blocking the reuptake of serotonin and increasing the amount available for transmission
through the brain. SSRI medications include citalopram (Celexa), Escitalopram oxalate
(Lexapro), Fluoxetine (Prozac, Prozac Weekly, Sarafem), Fluvoxamine (Luvox),
Paroxetine (Paxil), and Sertraline (Zoloft). Mixed reuptake inhibitors, also known as
serotonin and norepinephrine reuptake inhibitors (SNRIs), inhibit the reabsorption both
of serotonin and norepinephrine. Medications in this category include Venlafaxine
(Effexor) and Cymbalta (duloxetine). Other atypical anti-depressants include bupoprion
(Wellbutrin), nefazodone (Serzone), and mirtazepine (Remeron); the latter of these is the
only anti-depressant in the category known as receptor blockers (Mayo Clinic staff,
2002).
Treatment with anti-depressants has expanded to include other disorders, such as
minor depression, dysthymia, premenstrual dysphoric disorder, and some eating disorders
which frequently have a higher prevalence among women. The growth and expansion of
the anti-depressant market has increased the availability of these medications to treat a
variety of symptoms. SSRIs and SNRIs were ranked third and fourth in the leading
product categories in 2000 and 1999, respectively, according to prescriptions dispensed
(Latner, 2000 and Latner, 2001). In 2001, the drug Zoloft, an SSRI, ranked seventh for
total number of prescriptions dispensed in 2001 (Pharmacy Times, 2002). In 2002, two
SSRIs, Zoloft and Paxil, were included in the top 20 list for total scripts dispensed, and
SSRIs and SNRIs showed a 16% increase in unit sales over the previous year (Vaczek,
2003). In a study of national patterns for treatment of depression, Stafford, MacDonald,
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and Finkelstein (2001) estimate that between 1987 and 2001, the number of physician
visits by patients with depression increased from 14.4 to 24.5 million and the rate of antidepressant medication treatment increased from 70 to 89%.
Anti-depressants, therefore, represent a significant portion of the prescription drug
market, becoming standard fare in the treatment of depression and contributing to a
changing conceptualization and understanding of depression. Metzl and Angel (2003)
found that the portrayal of depression in the popular press has expanded popular notions
to include treatment for sub-threshold manifestations of the disorder. According to this
study, the popular press often conceptualizes a woman’s need for anti-depressant
treatment based on problems with marriage, motherhood, or menstruation rather than on
DSM symptom terminology, therefore expanding the range of problems considered
treatable and pathologizing those that were previously construed as normal problems in
womanhood (Metzl & Angel, 2003). This re-conceptualization of depression by the
popular press, combined with the expanded marketing and advertising of newer
pharmaceuticals has shifted the anti-depressant paradigm to include treatment for
constellations of symptoms which may not meet the threshold for a psychiatric disorder.
Indeed, prescribing trends for women seem to substantiate this altered notion of what
constitutes depression. Burt and Bernstein (2003) found that anti-depressants represent
the most frequently prescribed medications to women during visits to physician offices
and hospital outpatient departments. The overall increase (13%) in medications
prescribed to treat chronic illness, despite an absence of increased health care utilization
has been attributed to patient demand, prescribing practices of physicians , and the
availability of better medications (Burt & Bernstein, 2003).
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To recap, changing trends about what constitutes symptomatic and treatable
depression for women, combined with the availability and influential presence of new
anti-depressant medications are associated with an increase in the prevalence of childbearing-age women being treated with these medications. Women taking anti-depressant
medications face a great dilemma concerning whether or not to continue pharmacologic
treatment during pregnancy. Women faced with this decision may present to clinicians in
one of three categories: those who are planning a pregnancy but require maintenance
therapy for chronic and and/or recurrent depression; those who conceive while taking an
anti-depressant; and those who develop depression during pregnancy (Young, Campbell,
& Harper, 2002). Women seeking consultation for this dilemma present a difficult
challenge for clinicians because the Food and Drug Administration (FDA) has not yet
approved any psychotropic drugs for use during pregnancy (Nonacs & Cohen, 2002).
Even though limited studies indicate that some medications may be used safely during
pregnancy, many women choose to discontinue anti-depressants to avoid any risks that
may be associated with fetal and/or child development. For liability reasons and/or based
on limited knowledge about the risks associated with depression during pregnancy and
the postpartum period, some clinicians recommend that women discontinue these
medications for the duration of the pregnancy. However, untreated prenatal depression
presents its own set of risks, which can include poorer pregnancy and infant outcomes
(Oberlander & DePietro, 2003) as well as a difficult adjustment to the vulnerable period
after labor and delivery.
An awareness of the biopsychosocial aspects of PPD has significant implications
for clinical psychologists working in behavioral medicine and more traditional clinical
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settings. Clinicians working with psychotherapy clients who are either pregnant or
contemplating pregnancy and facing the medication cessation dilemma can assist these
clients in performing a risk-benefit analysis to aid them in their decision-making.
Clinicians in this type of setting can also assess, either formally or informally, a client’s
risk for developing PPD and offer an intervention which will help the client plan for any
problems she may experience in the postpartum period. In other words, clients who
decide to discontinue anti-depressant medication during pregnancy need to be assessed
for symptoms throughout pregnancy and provided supportive psychotherapy as well as
psychoeducation about the potential stressors associated with postpartum adjustment.
The efficacy of combining psychotherapy and medication to treat certain types of
depression has been increasingly supported in the research (Friedman, 2004; Otto et al.,
2005). However, clinicians should consider the use of cognitive behavioral therapy
(CBT) as an effective alternative for women who opt against taking medication.
Literature has supported the efficacy of CBT in the treatment of depression. Wagner’s
(2005) meta-analysis revealed that both SSRIs and CBT proved effective treatments for
depression and were superior to placebos. In a six year follow-up study of individuals for
whom anti-depressants were tapered and discontinued, Fava et al. (2004) found that CBT
treatment resulted in a significantly lower relapse rate than clinical management alone.
Clinical psychologists working in behavioral medicine settings will benefit from
an awareness of risk factors for PPD and be better-equipped to assess obstetrical
inpatients referred for depression consultations. Furthermore, they can provide training
and education to medical staff about the risk factors and symptoms of post-partum
depression. They can also be proactive in the prevention of PPD by increasing the
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knowledge and awareness of pregnant women and their families about the realities of
postpartum adjustment and the risks of developing PPD. Ideally this can be
accomplished by augmenting childbirth classes typically offered to pregnant women and
their partners. Behavioral medicine clinicians working in or affiliated with outpatient
obstetrical-gynecological practices have a plethora of opportunities for prevention and
intervention. For example, they can screen pregnant women to determine their level of
risk for developing PPD and postpartum women for actual symptoms of PPD. Clinicians
can interview women who screen positively for PPD to determine if a PPD diagnosis and
further psychological treatment is warranted.
To summarize, there are several ways that clinicians working in traditional
psychotherapy and behavioral medicine settings can intervene to assist clients with PPD
or PPD risk factors. However, current practices related to prevention and intervention of
PPD fall short of what is necessary to identify and treat at-risk pregnant women and
women who have become symptomatic in the postpartum. As a result, opportunities
abound for clinicians to screen and treat women and their families either to avert or to
cope with the potentially debilitating effects of a disorder which can deprive women of
experiencing the joys of parenthood and wreak emotional havoc on their families.
Symptoms of Postpartum Depression
Falling between the milder symptoms associated with the blues and the most severe
manifestation of symptoms found in postpartum psychosis, non-psychotic PPD represents
the middle range which affects between 10-20% of women (LLewlyyn, Stowe, &
Nemeroff, 1997). Even though the DSM-IV defines a postpartum onset of an episode of
depression as occurring within four weeks after delivery, onset varies and may even
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develop late in pregnancy. Typically, symptoms appear between six and eight weeks
postpartum (Nunacs & Cohen, 1998). Chaudron (2003) postulates that almost 50% of
PPD cases represent continuations of depressive episodes that began either before or
during pregnancy, estimating that only 15% of PPD episodes represent a woman’s first
episode of depression. Symptoms of PPD usually mimic those for major depression and
can include depressed mood, anhedonia, significant weight change, low energy, fatigue,
insomnia or hypersomnia, poor concentration, suicidal ideation, anxiety, and/or
obsessionality. Although suicide seems to be less common in PPD, guilt and agitation
seem to appear with greater frequency (Hendrick, Altshuler, & Suri, 1998).
Detecting PPD can be complicated by the overlap of depressive symptoms with
the changes in sleep, appetite, weight, libido, fatigue, and worry that frequently
characterize normal post-partum adjustment (Llewellyn et al., 1997). Although PPD is
frequently indistinguishable from non-postpartum depression, the research on its
presentation is mixed. For instance, Whiffen and Gotlib (1993) found that non-psychotic
PPD tends to be milder in severity and that 70% of women with this type of PPD met
only the diagnostic criteria for a minor depression. In contrast, Hendrick, Altshuler,
Strouse, and Grosser (2000) found that women with PPD were significantly more likely
to present with anxious features and a more severe symptom profile that took longer to
respond to pharmacotherapy than those with major depression unrelated to childbirth .
Expert opinions differ about whether or not PPD has a unique constellation of symptoms,
and it is likely that the presentation depends on the particular factor profile unique to each
woman.
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Despite the incidence data on PPD, experts estimate that approximately 50% of
women do not seek treatment for their symptoms even though they have the opportunity
for at least one contact with their obstetricians at the postpartum follow-up visit and for
frequent contacts with their children’s pediatricians during well- and sick-baby visits
(Chaudron, 2003; Lane et al., 1997). Medical professionals who do not screen women
for depression may be inadequately trained to recognize the difference between normal
adjustment and clinically significant symptoms of depression. Further, cognitive
distortions suggesting that this should be a happy and fulfilling time can cause feelings of
shame and guilt and make it difficult for women to acknowledge their distress.
Course and etiology of PPD
As stated above, identification of PPD proves difficult for afflicted patients as
well as physicians. Women may erroneously attribute the insidious onset of symptoms to
normal adjustment and therefore minimize self-reports of distress. The two most
predominant perspectives which elucidate the etiology and course of PPD and have
contributed to the most influential research on the topic include the feminist and medical
models. The feminist model explains the manifestation of PPD on the basis of
psychosocial factors, and the medical model offers a biological explanation of the
disorder. Research from both models informs the current study in order to enrich
awareness of the powerful and wide-ranging biopsychosocial factors that can influence a
woman’s experience.
The feminist model. Feminist theory postulates that women become disillusioned
by the incongruity between the realities of motherhood and the myth that motherhood is a
universally fulfilling experience for all women (Beck, 2002; Lewis & Nicolson, 1998). A
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substantial amount of research underlying feminist theory comes from qualitative studies
which use inductive analyses to identify constructs that are based on women’s accounts
of their own experiences with symptoms of PPD. One such study by Lewis and Nicolson
(1998) found that women conceptualize the onset of motherhood as a series of losses
which they frequently attribute to their own individual pathology, based on the pressures
induced by the stigma that motherhood should be a joyous time in a woman’s life. These
theorists postulate that society needs to de-mystify the experience of motherhood and
conceptualize it in more realistic terms which include both the negative as well as the
positive elements (Lewis & Nicolson, 1998) . Viewing PPD from a grief perspective,
feminist research suggests that women must first adjust their expectations and
acknowledge any losses associated with motherhood before they can change their
perspectives and evolve to the healing and reconstruction phases (Beck, 2002). Maunther
(1998) postulates that the manner in which women resolve the conflict between societal
expectations and the realities of motherhood determines whether or not they will become
depressed in the postpartum. In other words, women whose expectations of motherhood
exceed their subjective experience will likely become distressed if they cannot adjust
unattainable standards to be more congruent with their own realities.
Another aspect of this model focuses on the lack of social support available to
women in modern-day Western societies, specifically the relationship between the
absence of postpartum rituals and the prevalence of PPD. Rooted in the traditions of
many non-Western societies, these rituals provide mutual support to women during times
of emotional and physical vulnerability (Wile & Arechiga, 1999) and frequently include a
period of rest and confinement for the mother, practical and emotional support from other
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women, and social recognition for the mother’s new status (Mauthner, 1998) . For
example, the Latino practice of “the quarantine” frequently includes 40 days of rest for
the new mother, assistance with household chores from relatives, and abstention from
certain foods (Wile & Arechiga, 1999). Based on the African proverb “it takes an entire
village to raise a child” (p. 93), the postpartum practices of many African cultures include
participation and support from biological relatives and non-relatives alike, (Wile &
Arechiga, 1999).
Over the years, industrialization and ethnic blending in Western societies has
diminished the prevalence of many of these cultural traditions and promoted social
isolation and independent functioning. Research has demonstrated the relationship
between perceived social support and lower levels of depression in the postpartum
period. Collins, Dunkel-Schetter, Lobel, and Scrimshaw (1993) found that low-income
pregnant women who reported greater levels of support experienced quicker labor, higher
Apgar scores for their babies, and less post-partum depression. Another factor related to
diminished support for American mothers concerns the marked difference between
pregnancy and the postpartum in terms of the amount of attention women receive.
Pregnancy frequently includes baby showers, regular health check-ups, child-birth and
various pregnancy-related classes, and a plethora of written materials; yet, after the birth,
the focus shifts almost exclusively to the baby (Wile & Arechiga, 1999) while
simultaneously neglecting the needs of the new mother.
Medical model. Compared to the feminist model, the medical model views PPD
as a pathological condition based on physiological and biological factors to the exclusion
of social, po litical and economic factors (Beck, 2002). Indeed, the postpartum period is
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characterized by many physiological changes. Progesterone and estrogen levels increase
dramatically during pregnancy yet drop 200-fold, reaching pre-pregnancy levels between
three and seven days postpartum (Hendrick & Altshuler, 1999). Other changes include a
decrease in prolactin levels in non-breast-feeding women, thyroid dysfunction which
contributes to an increased rate of postpartum thyroiditis, and a decrease in the body’s
production of naturally occurring pain analgesics known as B-Endorphins (Hendrick &
Altshuler, 1999). Furthermore, some research has shown that estrogen and progesterone
influence neurotransmitter function and that the precipitous drop in postpartum levels of
these hormones may lower the levels of some neurotransmitters, such as serotonin and its
precursor, trytophan, resulting in depression (Hendrick & Altshuler, 1999).
In addition to these hormonal changes, symptoms experienced by new mothers
may include fatigue, hunger, chills and/or fever resulting from a hard labor, and pain
from a variety of sources including the surgical site (from a Caesarean section), post-birth
contractions, perineal bruises, tears, stitches, hemorrhoids, and tender breasts
(Dunnewold, 1997). Recovery from childbirth, whether for vaginal or caesarean
deliveries, is analogous to surgical recovery and can be a painful and physically
uncomfortable experience for many women (Dunnewold, 1997).
Risk factors
The reality for most women most likely represents a hybrid of the feminist and
medical models. Most women are exposed to multiple sets of internal and environmental
factors which potentially increase their risk of, or protection from PPD, underscoring the
importance of conceptualizing this disorder from a biopsychosocial perspective. In other
words, a combination of biological/physiological, psychological/emotional, and
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social/economic factors affects women’s adjustment to the postpartum and represents a
blend of risk and/or protective factors which influence outcomes. Exposure to multiple
risk factors increases the probability that a woman will develop PPD even though these
factors may be unrelated to the actual cause of the disorder (Beck, 2002) and may serve
only to predispose women to the risk.
Through a meta-analysis of 84 studies published in the 1990’s, Beck (2001)
identified 13 significant risk factors for PPD. Ten of these factors had moderate effect
sizes and include, in descending order, prenatal depression, self-esteem, childcare stress,
prenatal anxiety, life stress, social support, marital relationship, history of depression,
infant temperament, and maternity blues. The final three factors, marital status,
socioeconomic status, and unplanned/unwanted pregnancy, had small effect sizes (Beck,
2001). Because ten of these factors can be identified in pregnancy and are not limited to
the postpartum period, Beck has developed a revised version of the Postpartum
Depression Predictors Inventory (PDPI-R) designed to be administered in an interview
format to pregnant women to ascertain their risk of developing a postpartum depression
(Beck, 2002).
Because an analysis of the large number of variables which have been correlated
with PPD is difficult and unwieldy, the current study focused on the variables considered
most salient, based on additional research. For example, research has consistently
correlated depressed mood during pregnancy with PPD (Gotlib, Whiffen, Wallace &
Mount, 1991; Honey, Bennett, & Morgan, 2003; O’Hara, Rehm, & Campbell, 1982 ;
O’Hara, Schlechte, Lewis, & Varner, 1991); Righetti-Veltema, Conne-Perreard,
Bousquet, & Manzano, 1998). Gross, Wells, Radigan-Garcia, and Dietz (2002) analyzed
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data on recent mothers (N=14,609) from the Center for Disease Control and Prevention
(CDC) Pregnancy Risk Assessment Monitoring System (PRAMS) and found that 5.9% of
new mothers reported being depressed in the months after delivery. A more in-depth
analysis revealed that women who reported that pregnancy was a “very hard time” or
“one of the worst times of my life” were 4.6 times more likely to report symptoms of
PPD (Gross et al., 2002). Unfortunately, this particular study did not glean more specific
data from these women about the factors that contributed to their difficulties during
pregnancy. One can only speculate that the problems were related to physical and/or
emotional pain or distress, with the presumption that a portion of these women
experienced either a continuation or a resurgence of depressive symptoms. Another
study by Verkerk, Pop, Van Son and Van Heck (2002) found that a significant number of
women identified as being at high risk for PPD, based on either a personal or family
history of depression or depressive symptoms during pregnancy, were depressed at three
months postpartum compared to their low-risk counterparts, substantiating the link
between depressive history and PPD.
The variables social support and marital satisfaction have also been well-studied
in the literature. Gotlib et al. (1991) assessed women (N=730) at one month postpartum
and found that women identified as having PPD reported significantly lower levels of
marital satisfaction. O’Hara, Rehm, and Campbell (1983) found that depressed subjects
(N=11) reported having more frequent marital problems and receiving less instrumental
(help with household chores and child care) and emotional suppo rt from their social
network than did a group of non-depressed controls (N=19). Hock, Schirtzinger, Lutz,
and Widaman (1995) found that maternal marital satisfaction declined between the pre-
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and post-natal period and was significantly correlated with maternal depression at 9
months postpartum. Bernazzani, Saucier, David, and Borgeat (1997) found that
satisfaction regarding social support and difficult interpersonal relationships had an
indirect effect on PPD through higher levels of depression in the prenatal period.
Correlations between infant stress, which refers to infant temperament, infant
health problems, and/or premature birth, and PPD have also been noted in the research.
Davis, Edwards, Mohay, and Wollin (2003) found that 40% of mothers of very preterm
infants reported significant symptoms of depression spawned by high maternal stress.
O’Brien, Asay, and McCluskey-Fawcett (1999) found that almost half of the women
(N=45) who had delivered prematurely experienced symptoms of depression up to six
weeks after the baby was discharged from the hospital. In a comparison of depressed
(N=25) and non-depressed women (N=24), Hopkins, Campbell, and Marcus (1987)
found a significant correlation between infant-related stressors (neonatal complications
and infant temperament) and symptoms of PPD. Other research has also found a positive
correlation between PPD and mothers’ perceptions of their infants being temperamentally
difficult (Costa, Larouche, Dritsa, & Brender, 2000; Edhbor, Seimyr, Lundh, &
Widstrom, 2000; Wood, Hargreaves, & Marks, 2004). Sutter-Dallay, Murray, GlatignyDallay, and Verdoux (2003) found that behavioral characteristics of three day old infants
(N=468) predicted the occurrence of maternal depression at six weeks postpartum,
independent of other risk factors. By using an objective measure of neonate behavior,
Sutter-Dallay et al. (2003) were able to find a direct relationship between infants who
demonstrated poorer orientation (defined as the ability to attend to visual and auditory
stimuli and quality of overall alertness) and maternal development of PPD, suggesting
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that mothers experience higher rates of depression when they have difficulty interacting
with their less alert infants.
Another variable, a difficult birth experience includes reports of birth difficulty
due to pain, medical complications, and/or personal/emotional complications that
frequently occur after delivery by caesarean section. Boyce and Todd (1992) found that
women who had a caesarean section (emergency or non-emergency) had significantly
higher scores on a measure of depression than women who had either forceps or
spontaneous vaginal deliveries. Edwards, Porter, and Stein (1994) also substantiated the
findings of Boyce and Todd (1992) but also found a significantly higher rate of PPD
among caesarean subjects who had general but not localized (epidural) anesthesia. Koo,
Lynch, and Cooper (2003) found that women (N=55) who had an emergency caesarean
had approximately twice the risk of developing PPD than women (N=191) who had a
non-emergency delivery, suggesting that the salient factor has to do with the
unanticipated nature of the emergency rather than the surgery itself.
The relationship between PPD and the variable, child care stress, defined as the
stress a woman identifies in connection with her ability to care for her baby, has also
been reported in the literature. As previously reported, Beck’s (2001) meta-analysis
found a moderate correlation between childcare stress and PPD. Honey et al. (2003)
assessed depression and childcare stress in women (N=223) at six weeks postpartum and
found that participants who reported a high frequency of childcare stress were 16 times
more likely to have PPD compared to women who reported a low frequency of childcare
stress. Examples of childcare stress include difficulties quieting a baby’s cries and
problems feeding the baby (Honey et al., 2003). Leung (2002) also found that childcare
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stress was significantly predictive of PPD, suggesting that the problems women
encounter while caring for their newborns are associated with significant emotional
distress and subsequent symptoms of depression.
Assessment of PPD
Timing of assessment. Based on previous research revealing women’s reluctance
to report symptoms of PPD to their physicians, a formal assessment of all postpartum
women seems to offer the greatest opportunity for identification and subsequent referral.
Two localities which seem logical as places to administer screening include the offices of
obstetricians (ob/gyns), gynecologists, and pediatricians. Even though symptoms can
develop anytime during the first year after pregnancy, the postpartum checkup provides
ob/gyns with a critical opportunity to conduct formal screening. Dietrich et al. (2003)
conducted a study to address concerns about the capacity of ob/gyns to assess women for
depression. In the study, physicians reported higher levels of confidence discussing
psychiatric symptoms with patients, particularly in the postpartum, suggesting that there
have been improvements in the didactic mental health training received by ob/gyns
(Dietrich et al., 2003). The results of the random survey of 1,000 ob/gyns assert that the
current training improvements hold promise for women, but these results also identify a
need for additional training in the areas related to anti-depressant agents and assessment
of multiple risk factors (Dietrich et al., 2003). Corroborating the need to augment
physician training in behavioral health, a study of residents in North Carolina discovered
that an insufficient number of pregnant and postpartum women are actually being
screened for depression (Stevens & Diehl, 2003).
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Barring any complications, women do not see their ob/gyns except for the one
time postpartum visit. Therefore, women who are still asymptomatic or who have poor
insight or awareness during this time period may risk avoiding detection. On the basis of
this potentially lost window of identification, Chaudron (2003) asserts that pediatricians
have a unique opportunity to assess PPD on the basis of their contacts with mothers
during routine well-baby check-ups and any additional sick visits. In a subsequent study,
Chaudron, Szilagyi, Kotzman, Wadkins, and Conwell (2004) found a significant increase
in the detection of symptomatic women after implementing universal depression
screening during first year well-baby visits. Mandl, Alpert, and Homer (1998) found that
women whose infants have frequent outpatient sick visits to their primary care physicians
are more likely to exhibit symptoms of depression, suggesting a link between PPD and
excessive worry over the health of one’s infant. A nationwide random sample revealed
that most pediatricians had a general lack of knowledge regarding PPD and an
unfamiliarity with screening tools, suggesting the need for education and training prior to
implementing any type of assessment in the pediatric environment (Wiley, Burke, Gill, &
Law, 2004).
Women’s difficulties acknowledging symptoms of PPD, however, can potentially
hamper screening efforts, as evidenced by Tam, Newton, Dern, and Parry (2002) in their
efforts to screen women for PPD during well-baby visits in the first postpartum year. Of
160 study packets distributed to women at their first well baby visit, only seven women
agreed to participate. The authors attributed this low participation rate to women’s
difficulties acknowledging symptoms of PPD due to fears of being stigmatized (Tam et
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al., 2002) thus corroborating the need for increased awareness and acceptance of this
disorder.
Assessment instruments. Formal assessment measures include the recently
published Postpartum Depression Screening Scale (PDSS), as well as the Edinburgh
Postnatal Depression Scale (EPDS), the Postpartum Depression Checklist, the
Postpartum Adjustment Questionnaire, the Bromley Postnatal Depression Scale, and the
Schedule for Affective Disorders and Schizophrenia Pregnancy and Postpartum
Guidelines (Dunnewold, 1997). Until the development of the PDSS, the EPDS, a brief
10-item scale with excellent sensitivity and specificity, has been widely used in the
assessment of PPD (Dunnewold, 1997). Research indicates that the EPDS is an effective
adjunct to the clinical interview for the diagnosis of PPD (Evins, Theorfrastous & Galvin,
2000; Lee, Yip, Chiu, & Chung, 2000). Peindl, Wisner, and Hanusa (2003) found the
EPDS to be an effective screening instrument for high risk women with a history of PPD.
However, a systematic search of all published validation studies of the EPDS between
1987 and 2000 revealed that application of the EPDS to the general population tends to
result in a substantial proportion of cases identified as false positives (Eberhard-Gran,
Eskild, Tams, Opjordsmoen & Sven, 2001).
The newly designed PDSS has been strongly correlated both with the EPDS and
the Beck Depression Inventory-II (BDI-II) (Beck & Gable, 2001). In a comparative
study of the PDSS both with the EPDS and the BDI-II, Beck and Gable (2001) found that
the PDSS showed a higher combination of sensitivity and specificity when detecting
women either with major or minor postpartum depression. The PDSS identified 94% of
18 women identified with major PPD, compared to 78% and 56% identified by the EPDS
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and the BDI-II, respectively. Unlike the EPDS, the PDSS includes items written in the
context of new motherhood (Beck & Gable, 2001) and is based on 11 themes gleaned
from Beck’s qualitative research on PPD (Beck & Gable, 2003). By contrast, the EPDS
falls short in its exclusion of most of these themes (Beck, 1992).
Treatment
Although experts in the field concur about the treatment modality for severe
symptoms of PPD, there is less consensus regarding mild to moderate presentations of the
disorder (Altshuler et al., 2001). The fact that Boath and Henshaw (2001) conducted a
comprehensive literature review of treatments for PPD and identified only 30 articles
suggests that there is a dearth of treatment research. Based on the fact that antidepressants have not been proven to be completely risk-free during pregnancy and
breastfeeding, Boath and Henshaw (2001) suggest that research should concentrate on
effective psychological instead of pharmacological interventions (Boath & Henshaw,
2001). Findings from this study showed the majority of psychological interventions were
superior to routine primary care in treating PPD but failed to uncover which treatments
were superior to others in terms of efficacy (Boath & Henshaw, 2001).
Anti-depressant medication. Medication seems to be most effective for vegetative
and more functionally impairing symptoms such as sleep and appetite changes,
psychomotor agitation or retardation, and poor concentration (Jermain, 1992). Some
research suggests that PPD is more refractory to treatment than non-postpartum
depression. Based on a review of records of 26 women with PPD and 25 women with
major depression, Hendrick et al. (2000) found that women who sought treatment for
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PPD presented with more severe symptoms, took longer to respond to pharmacotherapy,
and frequently required two or more anti-depressant agents to elicit a treatment response.
Research on the administration of anti-depressant agents prophylactically in the
immediate postpartum period has provided mixed results. For example, Wisner et al.
(2001) randomly assigned non-depressed women with a history of PPD to treatment with
either nortriptyline or placebo immediately after giving birth and found no significant
differences in PPD outcomes, concluding that preventive treatment with an antidepressant did not protect women from becoming symptomatic. In contrast, an earlier
study by Wisner and Wheeler (1994) found that non-depressed patients with a history of
PPD who took anti-depressant medication within 24 hours after delivery had significantly
lower rates of relapse than those who deferred medication. In contrast with the more
recent study, the women in the earlier study were treated either with nortriptyline or the
medication deemed effective for a previous episode of PPD which may explain, in part,
the differential findings. On the basis of research in this area, Wisner, Parry, and Pintek
(2002) continue to assert that post-delivery prophylactic treatment with SSRIs or agents
to which there was a previously favorable response should still be considered; this is
based on the statistic that women with a history of one PPD episode risk a 25% rate of
recurrence. Wisner, Perel, Peindl, and Hanusa (2004) found that sertraline afforded a
better protection than a placebo against a recurrence of PPD in postpartum women with a
history of PPD who, however, were not treated for depression in the current pregnancy.
Therapy. Options for treating PPD include individual, group, and marital/family
therapy. Of 120 postpartum women who met DSM-IV criteria for major depression,
O’Hara (2000) found that women who were treated with interpersonal psychotherapy had
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a significantly greater reduction in scores than did wait–list controls, both on the Beck
Depression Inventory and the Hamilton Rating Scale for Depression. An earlier study by
Holden, Sagovsky, and Cox (1989) found nondirective counseling, cognitive-behavioral
therapy, and psychodynamic therapy were more effective than routine primary care in
reducing symptoms of PPD. In her book designed to be a guide for practitioners,
Dunnewold (1997) purports that treatment for the depressed mother should focus on
physical and emotional self-care, social support, and structure to ensure that the mother
understands the positive correlation between her own health and well-being and her
ability to be an effective care-giver and form an emotional bond with her baby.
Several studies have demonstrated the effectiveness of multiple sessions of CBT,
used alone or in combination with other treatments, in the treatment of PPD (Appleby,
Warner, Whitton, & Farragher, 1997; Chabrol et al., 2002; Cooper, Murray, Wilson, &
Romaniuk, 2003; Honey, Bennett, & Morgan, 2002; Prendergast & Austin, 2001). Based
on a sample of 35 women diagnosed with PPD with comorbid anxiety, Misri, Reebye,
Corral, and Millis (2004) found that CBT combined with antidepressants was equally as
effective as antidepressant monotherapy for acute symptoms. Although studies like these
suggest that CBT has not proven superior to other treatments for PPD (such as
medication and interpersonal therapy), particularly in the acute phase of the disorder, it
has some tenets which can be very helpful to depressed women in the postpartum. CBT
strategies such as relaxation training and cognitive restructuring can be used to help
reduce symptoms of anxiety, and sleep hygiene strategies can help women whose anxiety
and coping self-efficacy is exacerbated by sleep-deprivation (Dunnewold, 1997).
Furthermore, CBT can help depressed women modify distortions and erroneous beliefs
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about motherhood and enable them to set more realistic expectations of themselves and
others.
In terms of group therapy, treatment can include process groups led by trained
therapists, support groups facilitated by peers, or didactic/educational groups which focus
on specific topics (Dunnewold, 1997). Clark, Tluczek and Wenzel (2003) found that
scant research exists on efficacious group treatments for postpartum depression; based on
this finding, the authors sequentially assigned women identified with PPD either to a
relationship-focused mother-infant therapy group or to a wait-list control group. The
authors compared outcomes to a third group of women treated with individual
interpersonal therapy (IPT) sessions which were unique, based on the frequent inclusion
of infants and the strong focus on parenting and relational issues. Results revealed that
the women in the mother-infant and IPT interventions reported significantly fewer
symptoms on a post-treatment measure than did women in the wait-list condition. The
findings of the study support a treatment approach which targets the quality of the
mother-infant bond, family functioning, and the socio-emotional de velopment of the
child, in addition to the mother’s symptoms of depression. As the study indicates, this can
be accomplished either formally using the structure of the mother-infant group or
informally with individual IPT sessions which include relational components (Clark et
al., 2003).
Two recent studies regarding patient views about treatment for PPD yielded
information which has important implications for clinical psychologists. Chabrol,
Teissedre, Armitage, Danel, & Walburg (2004) provided information about PPD to
women who were three days postpartum, assessing the women’s intentions to breastfeed
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as well as their level of support either for psychotherapy or anti-depressants as the
preferred treatment for PPD. The participants were subsequently instructed to read a brief
passage which contained information about the potential risks of taking anti-depressants
while breastfeeding.

Results indicated that the women’s acceptability of anti-

depressants was significantly lower than that of psychotherapy both before and after the
information was presented. On the post-information measure, 95% of the 405 participants
indicated they would choose psychotherapy over PPD; 2% and 3% chose anti-depressants
or neither treatment, respectively (Chabrol et al., 2004), suggesting that women find
psychotherapy to be a more acceptable treatment for PPD than medication.
The second study found that British women treated for PPD were significantly
more satisfied with treatment by a multidisciplinary team of medical and mental health
workers than by treatment in routine primary care (Boath, Bradley, & Anthony, 2004).
The women in the multi-disciplinary treatment group were provided a unique
intervention, known as Parent and Baby Day Unit, offered in the setting of a specialized
psychiatric day hospital in England. Although the treatment was considered
comprehensive and included pharmacotherapy, individual and group therapies were
salient components. Both of these studies (Boath et al., 2004; Chabrol et al., 2004)
suggest that women regard treatment which includes psychotherapeutic components as
more acceptable and experience greater levels of satisfaction after this type of treatment
is delivered. When becoming symptomatic, it makes sense that women initially consult
with their physicians, simply because they have experienced more frequent contact with
them prenatally, during birth, and at the 6 week postnatal check-up. Although many
physicians prescribe medication as the first line of treatment for symptom relief, it seems
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that many women would prefer treatment alternatives if they were made available to
them. For clinical psychologists, this means establishing working relationships with
medical professionals to offer psychotherapeutic treatment alternatives to patients with
PPD.
PPD and child development
Research has shown that PPD can disrupt the maternal-infant bond, resulting in
acute infant distress and a potentially less favorable developmental pathway for the child
(Jacobsen, 1999). Much of the work in this area is based on the Mutual Regulation Model
(MRM) which asserts that the establishment of social relationships and the mutual
construction of meaning provide the foundation for a child’s understanding of the world
of objects (Tronick & Weinberg, 1997). The caretaker’s capacity to interpret and respond
appropriately to the infant’s communication is a critical component of this model. The
presence of PPD can interfere with a mother’s ability to meet the needs of her baby
adequately and, barring the buffering effects of any protective factors (such as easy infant
temperament and frequent interactions with healthy caretakers), may have de leterious
effects on the child’s capacity to develop normally.
In a meta-analysis of 19 studies, Beck (1996) found that PPD has a moderate to
large effect size in relation to the quality of interactions between mothers and infants
during the first year of life. Compared to non-depressed mothers, mothers with PPD
were less affectionate with their babies, less responsive to infant cues, and either more
withdrawn and affectively flat or more hostile and intrusive with their babies (Beck,
1996). Tronick and Weinberg (1997) distinguished between intrusive mothers who had
exhibited physically rough and verbally angry behavior toward their babies and
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withdrawn mothers who were more disengaged and unresponsive. The fact that infants of
the withdrawn mothers showed more distress (fussing and crying) than those of the
intrusive mothers suggests that infants prefer some type of interaction over no interaction
(Tronick & Weinberg, 1997).
Depressed mothers have negative cognitions which predispose them to distort
their perceptions regarding their children’s temperaments and their own ability to parent
competently and effectively (Teti & Gelfand, 1997). Because depressed mothers have
lower levels of self-efficacy regarding parenting abilities, they are more vulnerable to
making negative attributions about children with more difficult temperaments. (Teti &
Gelfand, 1997). Furthermore, the distress exhibited by infants of depressed mothers is
likely induced by a combination of the mothers’ cognitive distortions and an exacerbation
of the children’s temperaments as a result of depression-related maternal behavior (Beck,
1996). Beck (1996) found that infants of depressed mothers made fewer positive facial
expressions and vocalizations in addition to being fussier, less content, and more
avoidant. Righetti-Veltema, Conne-Perreard, Bousquet, and Manzano (2002)
corroborated these findings in their research, which revealed that depressed mother-infant
dyads presented fewer vocal/visual communications, fewer corporal interactions, and less
smiling.
Even though infant sleep disorders are prevalent in non-clinical as well as in
clinical populations, Hiscock and Wale (2001) found a significant relationship between
PPD and infant sleep problems. Cramer (1997) found that infant sleep disorders
diminished after depressed mothers were treated with psychotherapy. It is difficult to
ascertain if the infant actually sleeps less or if the depressed mother’s sleeplessness,
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agitation, and heightened state of arousal causes her to react to even minor infant sleep
disturbances; the reaction of most non-depressed women would be either to remain asleep
or to choose to ignore the disturbance (Cramer, 1997).
Finding a relationship between PPD and maladaptive child development that
occurs beyond the first year becomes more difficult. A meta-analysis by Beck (1998)
showed that PPD had a small but significant effect on children’s cognitive and emotional
development, specifically anti-social behavior and cognitive deficits. Murray, Sinclair,
Cooper, Ducournan, and Turner (1999) did a follow-up study which compared the
socioemotional behavior of 5-year-olds whose mothers had experienced depression in the
early postpartum months to a control group, whose mothers had not experienced
depression in the postpartum. These authors attributed certain problematic aspects of the
socioemotional behaviors displayed by the 5-year-olds in the experimental group to the
occurrence of PPD which was identified in their mothers at 2 months postpartum (Murray
et al., 1999). Even though the mothers in the study had recovered from the episode of
PPD by the time their children were 5 years old, the authors speculate that the difficulties
that PPD brings to the early mother-infant relationship may begin a cycle of problematic
interactions which continue to influence a child’s behavior, at least through the age of
five. Beck (1998) concluded, however, that the effects on maladaptive development
seem to weaken as children grow older. Because so many other factors can affect a
child’s development, it becomes increasingly difficult to correlate PPD with
developmental delays in later years. However, an episode of PPD predisposes women to
future episodes of maternal depression which could subsequently impede the children’s
developmental trajectory (Jacobsen, 1999).
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Pharmacologic treatment of depression during pregnancy
Current profile. No uniform standards exist for the pharmacologic treatment of
depression during pregnancy. The primary concern for patients and clinicians alike is the
short- and long-term effects that medication exposure in utero will have on the
developmental trajectory of the child. Because infants experience greater exposure to
psychotropic medications in utero (through placental passage) than postnatally via breast
milk, the American Academy of Pediatrics recommends prescribing women the lowest
dosage possible to control symptoms and minimize fetal risks (Misri & Kostaras, 2002).
Hendrick, Stowe, Altshuler, and Hwang (2003) found that concentrations of SSRIs were
lower in the umbilical cord than in the maternal serum for a sample of 38 women,
suggesting that a subthreshold dosage of the medication in a woman’s system passes
through to the placenta. Although metabolic changes in pregnancy (such as an increase
in blood volume and changes in gastrointestinal functioning) frequently require a dosage
increase in some drugs to maintain the therapeutic effect established before pregnancy,
research has shown that standard doses of antidepressant medication, specifically SSRIs,
seem to be adequate in pregnancy (Stewart, 1998). On the other hand, lowering a
previously effective dosage of anti-depressant in order to minimize fetal risk may in fact
increase a woman’s risk for a depressive relapse during pregnancy (Nonacs & Cohen,
2002).
The risks inherent in the placental passage of even milder forms of antidepressants are still not completely known and warrant multi-factorial consideration.
Guidelines developed on the basis of a review of literature published from 1971 to 1999
state that “anti-depressant medication treatment should be considered for pregnant

28
women who have major depressive disorder, as well as for those women in remission
from major depressive disorder, receiving maintenance medications, and deemed to be at
high risk for a recurrence if the medication is discontinued,” (American Psychiatric
Association [APA], 2000, p.21).
Clinicians’ utilization of a decision-making model designed to present
information in the context of a risk-benefit discussion can assist patients struggling with
the question of whether or not to continue medication during pregnancy (Wisner, Zarin,
Holmboe & Appelbaum, 2000). This type of method enables the clinician to take a case
by case approach and to collaborate with patients to formulate a biopsychosocial
conceptualization of the problem. The net result is that patients are better-equipped to
make informed choices and clinicians are better protected from liability risks provided
they have appropriate documentation (Wisner et al., 2000). In addition to including
individualized information from each women’s biological, psychological (personality
characteristics, coping skills), and social ( i.e. culture, marital, family, spirituality,
financial) domains, the decision-making process should provide not only guidelines from
the Food and Drug Administration (FDA), but also outcome data concerning treatment of
depression in pregnancy.
FDA guidelines. Based on data from human and animal studies, the FDA has
developed a five-category system (A, B, C, D, and X) to classify the reproductive safety
of various prescription medication (Nonacs & Cohen, 2002). The FDA considers
category A medications safe for use during pregnancy. Categories B through D represent
increasing degrees of risk, and Category X medications are contraindicated based on fetal
risks which significantly outweigh patient benefits. Fetal risk from drugs in Category C,
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which includes the majority of anti-depressant medications, cannot be ruled out because
of incomplete controlled human studies or because of animal studies which have shown
some risk (Cohen, 2001). By contrast, Category B medications demonstrate no evidence
of fetal risk on the basis of the following: animal studies show risk but human findings
do not OR animal studies show no risk but human studies do not exist (Ward et al.,
2000).
Many professionals argue, however, that the FDA’s system is flawed because
some drugs for which there are no documented adverse effects are “considered” safer
than others despite an extremely limited amount of data (Cohen, 2001) . In other words,
medication in Category B is not necessarily safer to use in pregnancy than a category C,
especially if the medication in question received the higher rating in the absence of
human data. In fact, Hendrick and Altshuler (2002) argue that a Category C medication
which received its rating on the basis of human studies showing low risk may be
preferable to a Category B drug for which no human data exists at all. A good example of
this confusion concerns the anti-depressant, buproprion (Wellbutrin), which has an FDA
category rating of B despite a dearth of available research. By contrast, the FDA assigned
a category C to fluoxetine (Prozac) based on low risk associated with administration of
extremely high doses to animals, despite the presence of a substantial number of human
studies (Cohen, 2001). This system not only confuses but can potentially mislead
clinicians who depend on these rating to advise patients. A committee on drugs
composed of Ward and colleagues (2000) have challenged the current FDA rating
system and recommend replacing it with a format which uses narrative statements to
summarize/ interpret available research data and provide estimates of developmental risk.
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The FDA has, in response to these challenges, organized several advisory panels to reevaluate the current rating system (Cohen, 2001; Ward et al., 2000).
Outcome data on use of anti-depressants in pregnancy. The four primary ways
medication exposure can affect the fetus include spontaneous abortions (miscarriage),
structural teratogenesis (birth defects), behavioral teratogenesis (behavioral or
neuropsychiatric symptoms in offspring), and perinatal syndromes (intoxication or
withdrawal symptoms in exposed offspring) (Ward & Zamorski, 2002; Wisner,
Gelenberg, Leonard, Zarin, & Frank, 1999). An interpretation of any studies on fetal
exposure to teratogens should take into consideration that the baseline incidence of birth
defects in the United States population is estimated to be between 2 and 4%, and the
cause is unknown for approximately 65% to 70% of these birth defects (Wisner, et al.,
1999).
Several changes have recently occurred regarding fetal exposure to SSRIs. First,
inconclusive data describing a neonatal withdrawal syndrome has resulted in an
agreement between the FDA and manufacturers of SSRIs and SNRIs to change labels and
to package inserts cautioning physicians and patients about potential adverse events that
have been associated with late trimester exposure to some SSRIs and SNRIs (Food and
Drug Administration, 2004; Moses-Kolko et al., 2005; Rosack, 2005). The labeling also
advises tapering and eventually eliminating the dosage of medication toward the end of
the third trimester to reduce and/or prevent any potential neonatal complications, a
practice not unanimously supported (Moses-Kolko et al.; Rosack, 2005; “SSRI
Pregnancy,” 2004). Second, a determination that fetal exposure to paroxetine (Paxil) in
the first trimester of pregnancy may increase the risk for cardiac malformations led the
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FDA to request that the manufacturer change the drug’s pregnancy category from C to D,
indicating a higher level of risk (“FDA Public Health Advisory,” 2005). Although
advising against the use of paroxetine in pregnancy, the FDA has stated that women
should not discontinue taking the drug without first consulting their physicians and that
any discontinuation should follow the directives outlined by the manufacturer (“FDA
Advising,” 2005).
With the exception of fluoxetine (Prozac) and citrapolam (Celexa), the
reproductive safety of many SSRIs is currently limited. Although there has been a
gradual increase in the number of clinical trials concerning the short-term effects to
infants exposed to anti-depressants in utero, longitudinal research designed to evaluate
the long-term developmental effects of exposure remains insufficient (Nunacs & Cohen,
2003). Some of the research is encouraging, albeit a bit confusing based on the fact that
studies vary in terms of the specific outcomes and medications being examined as well as
the period of exposure (i.e. first, second, and/or third trimester). Of the SSRIs, fluoxetine
(one of the original SSRIs) accounts for the largest percentage of studies, with
approximately 2400 in utero exposures documented in the literature as of 2001 (Cohen,
2001). Clinical trials of infants exposed to some of the newer SSRIs that came on the
market after fluoxetine are on the increase.
After the addition of FDA warning labels regarding potential neonatal toxicity
associated with late trimester exposure to SSRIs and SNRIs, Moses-Kolko et al. (2005)
reviewed the literature, finding most case reports about late trimester exposure to
fluoxetine and paroxetine. Their findings revealed that most neonates display mild
symptoms affecting central nervous system, respiratory, motor, and/or gastrointestinal
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functioning which usually remit within two weeks after supportive medical care (MosesKolko et al., 2005). Specific findings by Nordeng, Lindemann, Perminov, and Reikvam
(2001) found that infants exposed either to paroxetine, citalopram, or fluoxetine in the
third trimester of pregnancy experienced symptoms of withdrawal which lasted up to one
month postpartum. Findings by Costei, Kozer, Ho, Ito, and Koren (2002) also showed an
association between paroxetine and neonatal complications.
In a similar study, Laine, Heikkinen, Ekblad, and Kero (2003) found that infants
exposed in utero either to citalopram or fluoxetine exhibited significantly more
serotonergic symptoms (irritability, constant crying, shivering, and eating/sleeping
problems) during the first 4 days of life than did a group of unexposed infants . These
between-group differences, however, disappeared by 2 weeks postpartum, and results
from brain imaging revealed no pathological or structural differences between the
experimental and control group (Laine et al., 2003). The authors associate the
serotonergic symptoms of the exposed infants to the long half-life of SSRIs. In other
words, a steady level of an SSRI drug remains in the bloodstream for a prolonged period
of time even after medication is discontinued, explaining, in part, the infants’ symptoms
(Laine et al., 2003). An analogous study by Oberlander et al. (2002) found an association
between prolonged prenatal exposure to SSRIs and reduced behavioral pain responses
following a routine screening which necessitated blood collection from the baby’s heel,
an event considered to be noxious for the infant. These authors postulate that the
association between in utero exposure to SSRIs and blunted pain reactivity in infants may
reflect, at least in the short-term, an alteration in the function of neurotransmitters in the
brains of exposed infants (Oberlander et al,. 2002).
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On the basis of calls made to the California Teratogen Information Service and
Clinical Research Program, Chambers, Johnson, Dick, Felix, and Jones (1996) compared
pregnancy outcomes between 228 women taking fluoxetine and 254 not taking fluoxetine
during pregnancy. Findings revealed that the fluoxetine group did not experience an
increase risk for miscarriage or major fetal abnormalities; however, those women who
took fluoxetine during the third trimester experienced a higher risk of birth and postnatal
complications such as premature delivery, special care nursery admissions, and poorer
neonatal adaptation (Chambers et al., 1996), corroborating other findings of problematic
neonatal symptoms. Kulin et al. (1998) conducted a similar study which compared 267
women exposed to the SSRI’s fluvoxamine, paroxetine, or sertraline during the first
trimester to 267 unexposed controls. It is noteworthy that this study excludes fluoxetine
and that only 49 women in the SSRI group took the medication throughout their
pregnancies. Results showed no significant differences between groups on the following
pregnancy outcomes: major malformations, miscarriage, stillbirth, prematurity or infant
birth weight. Unlike the research by Chambers et al.(1996), this study was limited to
measures of structural teratology alone.
Utilizing their worldwide fluoxetine pregnancy registry, employees of Eli Lilly
and Company, the manufacturer of Prozac, studied the outcomes of 196 women exposed
to fluoxetine during the first trimester and found no statistically significant relationship
between maternal fluoxetine use during this time period and increased risk of fetal
malformation (Goldstein, Corbin, & Sundell, 1997). Their results could not, however,
completely rule out the presence of a marginally increased risk for fetal malformation
relative to fluoxetine exposure in the first trimester (Goldstein et al., 1997) In a related
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study, Cohen et al. (2000) found no differences in birth weight and acute neonatal
outcomes between infants exposed to fluoxetine in either early or late trimesters of
pregnancy. The study did, however, find a relationship between late trimester exposure
and frequency of special care nursery admissions which were brief in duration and
primarily observational in nature (Cohen et al., 2000).
Hendrick et al. (2003) prospectively followed 147 women taking SSRI antidepressants during any stage of pregnancy between June 1997 and May 2002 and found
the incidence of congenital anomalies to be comparable to general population rates. The
authors did, however, find reduced incidences of low birth weight infants and of preterm
births in this population, but they found that the low birthweight infants were born to
women who had taken relatively high doses of fluoxetine throughout their pregnancies.
The high dosage of medication taken by these women may, however, be associated with a
refractory depression of which poor appetite and insufficient weight gain may have been
a confounding factor which adversely impacted upon infant birthweight (Hendrick et al.,
2003). Other potential confounds include subject variability in anti-depressant and
trimester during which medication was taken, as well as the inclusion by some subjects of
other psychotropic medications taken in addition to anti-depressants (Hendrick et al.,
2003).
Simon, Cunningham, and Davis (2002) conducted an extensive review of hospital
and pediatric records of members of a prepaid health plan in the state of Washington to
determine the effects of tricyclic or SSRI anti-depressant exposure on birth and fetal
outcomes. Although the authors found no association between tricyclic or SSRI exposure
and either congenital malformation or developmental delay, they did report that SSRI
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exposure anytime during the pregnancy was associated with pre-term delivery and low
birth weight and that third trimester SSRI exposure was additionally associated with
lower Apgar scores (Simon et al., 2002). A similar study of women identified via the
Pregnancy Safety Hotline found no association between SSRI use in pregnancy and
major birth defects but did observe a trend for a slight decrease in infant birthweight with
prolonged exposure to an SSRI during pregnancy (McConnell, Linn & Filkins, 1998).
Two studies measured development in older children who had been exposed to
anti-depressants during pregnancy. Nulman et al. (1997) found no significant differences
on measures of global intelligence (IQ), language development, or behavioral
development between preschool age children of mothers who had received either
tricyclics or fluoxetine during pregnancy and a control group of non-exposed children.
Casper et al. (2003) conducted a similar study comparing the neurodevelopment of
children aged 6 to 40 months whose depressed mothers either took SSRIs during
pregnancy or elected not to take medication. Although the authors found no significant
differences between the groups on most birth outcomes ( including measures of mental
developmental ), they did find that SSRI-exposed children had lower APGAR scores and
lower scores on a measure of psychomotor development (Casper et al., 2003).
Untreated depression in pregnancy. Women experiencing depression during
pregnancy are also at risk for poorer pregnancy outcomes resulting from depressive
symptoms such as malnutrition, poor sleeping patterns, refusal of prenatal care, use of
illicit substances, psychotic symptoms, anxiety, and irritability (Young, Campbell, &
Harper, 2002). In a study of African-American women living in Baltimore, Maryland,
Orr, James, and Prince (2002) found a positive association between symptoms of
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maternal depression and preterm births. These results were corroborated by Dayan et al.
(2002) in a study of anxiety and depression in a sample of women living in France.
Kurki, Hiilesmaa, Raitasalo, Matilla, and Ylikorkala (2000) prospectively studied 623
pregnant women in Helsinki, Finland, finding a significant association between
depression and anxiety during pregnancy and the development of preelampsia (high
blood pressure) during pregnancy. Additionally, Hoffman and Hatch (2000) measured
the relationship between depression in pregnancy, fetal growth, and gestational duration
in 666 pregnant women and found an association between depression at 28 weeks and
low birthweight for the subgroup of women in a lower socio-economic class.
Three studies provide the most evidence-based foundation for the current study.
In one study, Einarson, Selby, and Koren (2001) address the relationship between
depression in pregnancy and discontinuation of psychotropic medication during
pregnancy. Of the 36 women who participated in the study, 34 abruptly discontinued
their anti-depressant or anti-anxiety medications, primarily for fear of harming the
developing fetus. Seventy percent of these women experienced adverse psychological
and physical effects, and a smaller number experienced psychological effects only.
Further analyses revealed that almost one-third of the women reported suicidal ideation;
four required hospitalization; one decided to have a therapeutic abortion, and one selfmedicated with alcohol. After counseling, 61% of the women in the study resumed taking
their medications with no adverse birth outcomes reported (Einarson et al., 2001).
The second more recent study by Marcus, Flynn, Blow, and Barry (2005)
identified 316 pregnant women who had taken antidepressant medication within two
years prior to conception. 248 women discontinued medication throughout pregnancy
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and 68 women continued medication throughout pregnancy; both groups demonstrated
symptoms with no significant differences between depression scores (Marcus et al.,
2005). The study was unable to ascertain whether or not obstetricians “were aware of
their patients” use or non-use of medication and also found that “most of the women who
discontinued medication were not in mental health treatment and unlikely to have been
engaging in prevention strategies or receiving regular medication visits or adjunctive
psychotherapy” (Marcus et al., 2005, p. 27). This suggests that the risk of relapse for
women who stopped medication was heightened by the absence of other modes of
treatment which could have assuaged symptoms. Of interest to the current study is the
fact that the study sample (women on medication prior to conception) represented only
11% of approximately 3500 women screened (Marcus et al., 2005), providing evidence
for the difficulty of finding an adequate sample size when the pool of potential
participants is smaller (as was the case in the current study).
In the most recent study measuring maternal mood in pregnancy, Cohen et al.
(2006) found that women who discontinued anti-depressant medication relapsed at a
significantly higher rate during their pregnancies than did their counterparts who
maintained their medication. Criteria for the study included current or recent antidepressant treatment proximate to conception and compared both discontinuers and
continuers using the Structured Clinical Interview for DSM-IV and the Hamilton Rating
Scale for Depression. Of the entire sample of 201 women, 43% experienced a relapse of
depression. More specifically, 21% of the 82 women who stayed on medication during
pregnancy relapsed into depression compared to 68% of the 44 women who discontinued
medication (Cohen et al., 2006). The findings in this study clearly support the
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relationship between discontinuing medication proximate to pregnancy and symptoms of
depression in pregnancy, and they provide a logical preface to the question posed by the
current study regarding what happens to this already vulnerable subgroup of depressed
discontinuers in the postpartum.
According to Dr. Lee Cohen, the Director of Perinatal and Reproductive
Psychiatry Clinical Research Program and Associate Professor of Psychiatry at Harvard
Medical School, the practice of “tapering or discontinuing psychiatric medication before
labor and delivery should be reexamined because it puts mothers and their babies at risk,”
(Cohen, 2001, p.10). All women, especially those with a depressive history, are at risk
for developing symptoms of depression during the emotionally vulnerable postpartum
period. Therefore, withdrawing treatment from women when they are about to enter a
period of increased risk is precarious and may lead to more severe symptoms of
postpartum depression (Nonacs & Cohen, 2002). The question remains: Are women who
suffer through depression during pregnancy because they believe they are protecting their
developing child from medication exposure setting themselves up for an episode of
postpartum depression which presents its own risks to the mother-baby bond and to the
child’s developmental trajectory?
Issues Related to Chronic and Recurring Depression
For the purposes of the current study, women in the postpartum who either
discontinued or who continued taking anti-depressant medication throughout pregnancy
can be conceptualized as having a history of depression, regardless of whether this
episode represents a first episode, a recurrent episode, or a chronic unremitting course of
treatment. Understanding the literature regarding relapse and recurrence of depression
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has significant implications for postpartum women with a history of depression. The
current study postulates that a return of depressive symptoms after a woman discontinues
anti-depressant medication during pregnancy constitutes a relapse of the current episode.
If this gap in treatment continues, symptoms are likely to worsen or, at best, remain
steady. However, once these symptomatic women experience the elevated stress
associated with the postpartum, the risks for experiencing a more severe episode of
depression increase.
Relapse prevention. A panel of representatives from the disciplines of psychiatry,
psychology, pharmacology, epidemiology, internal medicine, and the general public
concluded that recurrent mood disorders are under-diagnosed and under-treated
(Consensus Development Panel, 1985). The panel distinguished between “relapse” and
“recurrence”, defining the former as an “exacerbation of an ongoing episode after an
initial suppression of symptoms” and the latter as a “new episode following a complete
recovery that has lasted for at least several months” (Consensus Development Panel,
1985, p.470). According to information gleaned from the panel, approximately 50-85%
of patients with a major depressive episode will have at least one subsequent episode in
their lifetimes (Consensus Development Panel, 1985). This has tremendous implications
for postpartum women with a history of depression. Furthermore, 15-20% of patients
with a recurrent episode of depression do not sustain full recovery and may experience
symptoms for two years, and 50% of this group who do experience recovery are likely to
have a recurrence within the first two years (Consensus Development Panel, 1985). For
postpartum women who were treated in pregnancy for a recurrent episode of depression,

40
discontinuing medication seems risky, given the statistics which show that full recovery
may take up to 2 years.
The panel acknowledged the risks inherent in offering preventive anti-depressant
drug treatment to pregnant women and to the population in general, considering the
unknown risks that may be posed by long-term use of these drugs. However, they
concluded that appropriate and collaborative long-term treatment which involves the
patient, doctor, and family can help patients protect themselves from the potentially
deleterious effects of relapse and recurrence (Consensus Development Panel, 1985).
Clinical psychologists can also play an important role on this team of collaborators,
whether they are working with existing psychotherapy clients or consulting in a
behavioral medicine setting.
Research has supported the assertions of this panel. Judd et al. (2000) found that
patients who experienced residual, albeit subthreshold, symptoms after their first lifetime
major depressive episodes had significantly more severe and chronic future episodes of
depression than those who experienced a full recovery. This has implications for
pregnant women who discontinue anti-depressant treatment, especially if they are still
symptomatic, because they are approaching the postpartum period, “a time of heightened
risk for affective illness,” (Nonacs & Cohen, 2003, p.560). In other words, the possibility
exists that disrupting treatment could worsen the prognosis and cause an exacerbation of
depressive symptoms in the postpartum period.
Another study by Lin et al. (1998) found that 37.1% of 251 primary care patients
diagnosed either with major or minor depression reported a relapse in the year after acute
and continuous phase treatment. According to the authors, the two major risk factors

41
associated with relapse were a history of two or more episodes of major depression, two
years of chronic mood symptoms, and/or presence of subthreshold symptoms of
depression for seven months after beginning treatment with anti-depressant medication
(Lin et al., 1998). Interestingly, 76.8% of the study sample were female, further
underscoring a woman’s risk for recurrent episodes of depression. And, the postpartum
period has certainly been identified as a risky time, especially if treatment was
interrupted during pregnancy .
Melfi et al. (1998) found that 25% (N=4052) of Medicaid patients taking antidepressant medication experienced a relapse or recurrent episode of depression during a
2-year follow-up period. Although those patients who maintained their drug therapy
were the least likely to experience a relapse or recurrence of their depression, those who
prematurely discontinued medication risked a 77% percent chance of experiencing a
relapse/recurrence (Melfi et al., 1998). This research has significant implications for the
current study, because pregnant women who prematurely discontinue medication fall into
this category and face a substantial risk of relapse or recurrence.
Effects of long-term use of anti-depressants. The acute phase of antidepressant
treatment lasts until symptoms remit and it is followed by a continuation phase in which
treatment continues for four to nine months to prevent symptom relapse (APA, 2000;
Byrne & Rothschild, 1998; Keller, Kocsis, Thase, & Gelenbert, 1998; Winkler et al.,
2002). Following the continuation phase, patients at increased risk for recurrent episodes
are frequently advised to receive maintenance treatment that varies in length, depending
on the frequency and severity of recurrences, treatment tolerability, and individual
preferences (APA, 2000; Winkler et al., 2002). Some high risk patients with chronic
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depression may require a lifetime course of treatment (APA, 2000) to prevent recurrent
episodes. Keller et al. (1998) studied patients with chronic depression and discovered
that sertraline afforded significantly greater protection from recurrence than a placebo,
supporting the need for indefinite maintenance treatment in some cases. The Keller et al.
(1998) study has implications for the current study, especially for the population of
postpartum women who receive long-term treatment with anti-depressants prior to
pregnancy. The long-term effects of prolonged use of SSRIs on brain function are,
however, not clearly understood. Researchers have differentiated between the short-term
symptoms frequently associated with medication discontinuation and the longer-term
effects associated with symptoms akin to tolerance.
Regarding short-term discontinuation effects, the literature discusses withdrawallike symptoms which can include dizziness, nausea, headache, nervousness, and insomnia
(Haddad, 2001; Rosenbaum, Fava, Hoog, Ascroft & Krebs, 1998). Usually temporary in
duration, these symptoms vary according to the particular SSRI taken . Based on an
analysis of pertinent anti-depressant withdrawal studies between 1985 and 1996, Therrien
and Markowitz (1997) concluded that all SSRIs, regardless of dosage or treatment
duration, had the potential to cause withdrawal-like symptoms when abruptly
discontinued; however, most symptoms did not persist beyond 25 days of medication
discontinuation. Recommendations for symptom minimization include a gradual tapering
instead of an abrupt discontinuation of the medication. However, clinicians vary
considerably in their suggestions for duration of tapering, with some suggesting 1-2
weeks (Therrien & Markowitz, 1997) and others, despite a lack of empirical evidence,
promoting a year-long tapering process predicated on the notion that the “brain needs
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months, rather than days to adjust to the changes associated with stopping a medication”
(Winkler, Tauscher, & Kasper, 2002, p.66). This variability in tapering recommendations
certainly poses a dilemma for pregnant women contemplating medication
discontinuation. If they abruptly discontinue medication as soon as they discover they are
pregnant, they risk suffering a short-term bout of withdrawal-like symptoms and a relapse
of depressive symptoms. If they taper the medication gradually, their unborn babies risk
the potential consequences of medication exposure and the mothers themselves still risk a
relapse of depressive symptoms after the tapering ends.
The research regarding long-term effects of prolonged use of SSRIs on brain
function is less clear. A description of how SSRIs decrease symptoms of depression may
illuminate an understanding of the potential long-term effects cited in the literature.
Designed to prevent the reuptake of serotonin by the presynaptic receptors, SSRIs
prolong the amount of time that serotonin remains in the synaptic cleft and, therefore,
increase the concentration without altering the total levels of serotonin in the brain
(Popik, 1999). Transmission is facilitated because more serotonin is available to bind
with the postsynaptic receptors.
The impact that SSRIs have on the postsynaptic receptors is less clearly
understood and seems to be implicated as a factor affecting long-term outcomes of
prolonged use. Yatham et al. (2000) hypothesized that, during depression, the (untreated)
brain compensates by reducing the number of postsynaptic receptor sites, which may
offer an explanation about why some depression remits spontaneously. In other words,
fewer postsynaptic receptor sites decrease the amount of serotonin required for
transmission, thus diluting the effects that the reuptake of serotonin by the presynaptic
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receptors has on depression. The effect of SSRIs on the density and function of
postsynaptic receptors has shown mixed results. Of primary concern is the possibility
that prolonged use will increase the number of postsynaptic receptor sites and, therefore,
require greater amounts of serotonin in the synapse to facilitate transmission throughout
the brain. One study found an association between treatment with paroxetine and an
increase in these receptors, yet other studies showed that SSRIs either reduced or had no
effect on the number of postsynaptic receptors (Zanardi et al., 2001). Massou et al.,
(1997studied a small sample of six patients, finding an association between chronic
treatment with SSRIs and an “up-regulation” (increase) of postsynaptic receptors in the
frontal lo bes.
Byrne and Rothschild (1998) conceptualize these cellular adaptations to
prolonged SSRI use as one type of pharmacologic tolerance defined as
“pharmacodynamic tolerance.” The other type, described as “pharmacokinetic tolerance”,
is defined as a reduction in a drug’s concentration. A meta-analysis of studies since 1966
revealed that 9% to 57% of patients experienced a loss of anti-depressant efficacy during
maintenance treatment, citing pharmacologic tolerance as one possible explanation
(Byrne & Rothschild, 1998). In a review of the clinical literature suggesting that longterm treatment with anti-depressant drugs may worsen the course of depression, Fava
(2003) suggests that the cellular changes associated with pharmacodynamic tolerance
increase an individual’s biochemical vulnerability and represent one of the potential
deleterious effects of prolonged use.
Effective treatment for symptoms of tolerance includes increasing the medication
dosage, but again, the research shows mixed results. Fava et al. (1995) found that
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patients who relapsed during long-term treatment with fluoxetine recovered when the
dosage was doubled. However, in a similar study Baldessarini, Ghaemi, and Viguera
(2002) found that doubling the dose of fluoxetine for 35% of patients who relapsed
during long-term fluoxetine treatment had no effect on depressive symptoms.
Fava (2003) also speculates that anti-depressants may induce sensitization effects,
similar to those induced by amphetamines and cocaine, referring to a “long-lasting
increment in response occurring on repeated presentation of a stimulus that reliably elicits
a response at its initial presentation,” (p. 128). Acknowledging the difficulty involved in
testing this hypothesis, Fava (1999) cites only one study by Young, Cooke, and Levitt
(1995) which has attempted to verify the sensitization effects of anti-depressants.
Although this particular study found that patients with past anti-depressant treatment had
more subsequent depressive episodes of longer duration, it did not address the possibility
that the subjects experienced a more severe and refractory course of illness (Fava, 1999;
Young et al., 1995).
To summarize, there is a dearth of data to support the speculation that long-term
anti-depressant treatment can have deleterious effects on the course of depression. Fava
(2003) acknowledges the methodological and ideological obstacles involved in studying
this phenomenon in a scientific way and recognizes how the commonly held assertions
about maintenance treatment will continue to be reflected in clinician attitudes, beliefs
and, therefore, prescribing practices. In other words, it is likely that clinicians will
continue to advise individuals with chronic depression to maintain treatment with antidepressants to prevent recurrence. Furthermore, the paradigm shift in prescribing antidepressant medication for patients whose symptoms do not meet the threshold for clinical
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depression suggests that anti-depressants have become a mainstream solution for many
individuals seeking relief from symptoms that range from the very mild to the very
severe. At this juncture, research suggests that premature discontinuation and long-term
use are associated with an exacerbation of symptoms regardless of whether or not they
represent an incomplete recovery/relapse, a recurrence, or tolerance.
Summary
A serious and frequently underreported psychiatric disorder, PPD can have
deleterious and, in extreme cases, life-threatening effects on women, children, and
families. Stigma and lack of uniform screening procedures contribute to the inadequate
detection of symptomatic women, despite the availability of reliable and valid assessment
tools like the PDSS and the EPDS. Routine assessments at the 6-week postpartum
appointment and well-baby visits offer an opportunity to detect symptomatic women
during critical times.
A plethora of risk and protective factors are associated with PPD, underscoring
the importance of conceptualizing the disorder from a biopsychosocial perspective to
inform more comprehensive assessment and treatment strategies. Some noted risk factors
include a history of depression, depressed mood during pregnancy, infant-related stress,
and inadequate social support, to name a few. Treatment for PPD can include antidepressant medication and/or various types of therapy. Untreated PPD can have
deleterious effects on the mother-infant bond, potentially establishing a template for
problematic parent-child interactions in the future. Although PPD has also been
associated with poorer, short-term developmental outcomes, the relationship between
PPD and maladaptive development beyond the first year has been more tenuous.
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The factor of interest to the current study concerns the relationship between the
discontinuation of anti-depressant medication and the development of PPD. Because
women of childbearing age are being increasingly prescribed anti-depressant medication
to treat even minor symptoms of depression, they frequently face a dilemma about
whether or not to continue treatment when they become pregnant. Based on a lack of
comprehensive research on outcomes of infants exposed to medication in utero, many
women choose to stop medication for fear of harming their developing baby at the
expense of risking a return of their own symptoms of depression. They may be able to
withstand the return of some symptoms during pregnancy; however, their risk of
experiencing a clinical level of depression increases during the postpartum period, a time
of heightened emotional vulnerability and stress for most women, even those with no
known history of depression. Women who were on maintenance anti-depressant therapy
for chronic and recurrent depression may face an even greater risk of medication
discontinuation based on speculative changes associated not only with prolonged
medication use, but also with the chronic nature of their illnesses.
Women at increased risk for a return of symptoms during pregnancy and/or a
clinical level of PPD as a result of medication discontinuation need assistance in making
informed risk-benefit analyses and in obtaining alternative forms of treatment to cope
with symptoms in depression and in the postpartum. Clinical psychologists working
either in traditional outpatient therapy or behavioral medicine settings can play a critical
role in the prevention, assessment, and treatment of PPD. In summary, the review of
relevant research on PPD consistently points to the need for increased awareness and
education. The ability to conceptualize the risk factors for PPD from a biopsychosocial
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perspective will inform assessment and treatment, specifically with regard to the factors
addressed by the current study.
Purpose
Because the postpartum period represents a time of physiological and emotional
adjustment for all women, those at higher risk for post-partum depression seem to be
particularly vulnerable. The current study concerns whether or not discontinuation of
treatment with anti-depressant medication exacerbates a woman’s risk. Women with
chronic depression who take medication prophylactically may be especially vulnerable to
a more severe relapse, based on research (Fava, 2003; Massou et al., 1997; Zanardi et al.,
2001) showing that long-term use may be associated with permanent neurochemical
changes. Further, women being treated for more acute episodes of depression may
prematurely discontinue treatment prior to a full recovery and experience a continuation
of symptoms throughout pregnancy; these may then be exacerbated in the postpartum
period.
The primary purpose of the current study is to determine the relationship between
the discontinuation of anti-depressant medication and the development of post-partum
depression, determining if persons who decide to discontinue treatment during pregnancy
are at risk for an episode of postpartum depression. The current study will also attempt to
uncover additional factors which may be associated with PPD. Having this knowledge
will help to enlighten both the medical and mental health communities by helping
patients conduct more informed risk-benefit analyses regarding medication use during
pregnancy; it will also aid in the identification of patients at risk for developing PPD.
Clinical psychologists will benefit by understanding and educating clients about the risks
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and realities of this disorder and by offering preventive screening as well as postpartum
assessment either in traditional outpatient therapy or behavioral medicine settings.
Furthermore, the increase in education and awareness may have the effect of increasing
the number of symptomatic women who seek psychological treatment either on their own
or via a referral from their physicians. If the results of the study show that women
increase their risk for PPD when they discontinue anti-depressants during pregnancy,
clinical psychologists may increase their abilities to offer alternative therapies to women
suffering from depression throughout their pregnancies and into the postpartum period.
Hypotheses
The primary research hypothesis concerns the relationship between
discontinuation of anti-depressant medication during pregnancy and postpartum
depression. Specifically, the study hypothesizes that women who discontinue antidepressant medication during pregnancy will experience PPD at a higher rate than those
who either continued or restarted pharmacological treatment during pregnancy; the study
also includes a control group of women who were not taking anti-depressant medication
when they became pregnant. This hypothesis will be tested by comparing scores on a
postpartum depression screening instrument (the dependent variable) between all three
groups of women (the independent variable). Using the subgroup of women who
discontinue anti-depressant medication during pregnancy, the secondary hypothesis
asserts that those on maintenance therapy who had taken anti-depressants for the previous
nine months or more (APA, 2000; Byrne & Rothschild, 1998; Keller, Kocsis, Thase, &
Gelenbert, 1998; Winkler et al, 2002) will experience more severe symptoms of PPD.
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Based on the relationship between PPD and several risk factors already identified
in the literature, the third hypothesis contends that there will be a negative or positive
correlation between PPD and the following variables:
1) Pregnancy Mood (item # 26 on the postpartum survey); positive correlation.
2) Childcare stress [the stress of providing daily infant care (item #28 on the
postpartum survey)]; positive correlation.
3) Emotional Suppo rt (item #23 on the postpartum survey); negative correlation.
4) Instrumental Support [refers to help with household chores and hands-on help
with child care (item #25 on the postpartum survey)]; negative correlation.
5) Marital satisfaction (item #5 on the postpartum survey); negative correlation.
6) History of symptoms and/or treatment of depression (item #41 on the
postpartum survey); positive correlation.
7) Baby temperament (item #20 on the postpartum survey); positive correlation.
8) Birth experience (item #15 on the postpartum survey); positive correlation.
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Chapter 2
Method
Inclusion and Exclusion Criteria
Participation was voluntary and anonymous and included volunteers who were
female patients being seen for their routine postpartum appointment which normally
occurs between three and eight weeks after delivery. Participation was limited to those
older than 18 who had single births and were able to understand written and spoken
English; if unable to speak, write and understand English, a family member or friend had
to be available to assist them with any language barriers. Toward the end of the study, in
an attempt to equalize groups for analysis, participation was limited to women who took
either anti-depressant medication proximate to conception or began/restarted medication
sometime during their pregnancy.
Exclusion criteria included those under age 18, those who had a multiple birth,
and those taking either tri-cyclic anti-depressants, MAO Inhibitors, mood stabilizers, or
anti-psychotics medications. Participants who returned incomplete survey materials were
also excluded, as well as those not willing to volunteer to participate in the study. Toward
the end of the study, in an attempt to equalize groups for analysis, women who were not
taking anti-depressant medication proximate to conception or who did not begin/restart
taking medication at any time during their pregnancy were excluded.
Participants
The majority (99%) of the participant group included patients of an
obstetrical/gynecological practice which has offices in Lemoyne, Carlisle, and Hershey,
Pennsylvania, as well as an affiliate office in Harrisburg, Pennsylvania. One percent of
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the participants were patients of the PinnacleHealth Women’s Outpatient Health Center
in Harrisburg, PA, a site added six months after the study’s inception. Participation
occurred during the postpartum check-up which is typically scheduled approximately 6
weeks after delivery.
A sample of 202 women participated in this study. Twenty-six responses were
unusable for the following reasons: twenty-two were returned incomplete and four did
not meet study criteria because they indicated a multiple birth (i.e. twins). Participants
reported a mean age of 30.22 years (SD=4.93) with age ranging from 18 to 42 years.
Of the 99% of participants who were high school graduates or equivalent, 27.7%
reported having had some college credits and 36.6% had 4-year college degrees (See
Table 1). Regarding race, marital status, and income, the majority of the sample were
white (88.6%), married (89.6%), and had annual household incomes above
$40,000(83.2%). (See Tables 2, 3, and 4).
Almost half of the sample (49%) had only one child; the rest reported having two
or more children. Seventy percent of participants had a vaginal delivery but the other
30% had delivery by caesarean section (See Table 5). Almost thirty-two percent of the
sample reported having a history of depression (see Table 6), with 12.4% of multiparous
women reporting a history of symptoms of postpartum depression with prior births.
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Table 1
Years of Education (N = 202)
________________________________________________________________
Education

Frequency

Did Not Complete
High School

Percent

Cumulative Percent

2

1.0

1.0

High School Graduate

37

18.3

19.3

Some college

56

27.7

47.0

College Degree

74

36.6

83.7

Graduate Degree

33

16.3

100.0

Total

202

100.0

100.0

Table 2
Race (N = 202)
________________________________________________________________________
Race
Black or African American

Frequency

Percent

Cumulative Percent

12

5.9

5.9

Hispanic or Latino

6

3.0

8.0

Asian

5

2.5

11.4

White

179

88.6

100.0

Total

202

100.0

100.0

________________________________________________________________________
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Table 3
Marital Status (N = 202)
________________________________________________________________________
Marital Status

Frequency

Percent

Married

181

89.6

89.6

Partnered

13

6.4

96.0

Divorced

1

.5

96.5

Separated

2

1.0

97.5

Single

5

2.5

100.0

202

100.0

100.0

Total

Cumulative Percent

________________________________________________________________________

Table 4
Gross Annual Household Income (N = 202)
________________________________________________________________________
Income

Frequency

Percent

Cumulative Percent

<$20,000

7

3.5

3.5

$20,000-$40,000

27

13.4

16.8

$40,001-$75,000

95

47.0

63.9

$75,001-$100,000

52

25.7

89.6

> $100,000

21

10.4

100.0

Total
202
100.0
________________________________________________________________________
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Table 5
Type of Delivery (N = 202)
_______________________________________________________________________
Type of Delivery

Frequency

Percent

Cumulative Percent

Planned C-section

34

16.8

16.8

Induced Vaginal

53

26.2

43.1

Vaginal

89

44.1

87.1

Emergency C-section

26

12.9

100.0

202

100.0

100.0

Total

________________________________________________________________________

Table 6
Depression Treatment History (N =202)
________________________________________________________________________
Depression Treatment History
No history depression

Frequency

Percent

Cumulative Percent

138

68.3

68.3

Symptoms (no treatment)

12

5.9

74.3

Medication

24

11.9

86.1

Therapy/Counseling

10

5.0

91.1

2

1.0

92.1

16

7.9

100.0

202

100.0

100.0

Other
Medication and Therapy
Total

________________________________________________________________________
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Measures
Measurements of postpartum depression were obtained using the PDSS, a
measure which requires at least a third-grade reading ability (Beck & Gable, 2002). The
PDSS yields a total score which breaks into one of three levels: 80 or above indicates a
positive screen for major postpartum depression; 60-79 indicates significant symptoms of
postpartum depression (positive screen for depressive disorder NOS); 59 or below
indicates normal adjustment. The PDSS also includes the following seven symptom
content scores, each containing an identified cutoff score which indicates the presence or
absence of a significant cluster of symptoms: sleeping/eating disturbances;
anxiety/insecurity; emotional lability; mental confusion; loss of self; guilt/shame; suicidal
thoughts. Items that have no response (or more than one response) will be given the
median response value printed in bold type on the scoring sheet. A score of four or more
on the inconsistent responding index suggests that the respondent may have attention or
comprehension problems, which may reflect cognitive impairment but warrants collateral
data to confirm (i.e. interview with patient). All scores on the PDSS are discrete variables
with whole number values.
In terms of reliability, the PDSS demonstrates excellent internal consistency with
an alpha coefficient of .97 for the total score and coefficients ranging from .83 to .94 for
the symptom content scales (Beck & Gable, 2002). Content validity measures of the
PDSS show that each of the seven content scales correlate more strongly with the total
score than with each other, indicating that they represent a better index of general PPD
symptoms than symptom clusters measured by the other content scales (Beck & Gable,
2002). The PDSS also has good convergent validity as indicated by its strong correlations
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with the BDI-II (r=.81, p<.0001), the EPDS (r=.79,p<.0001), and the Structured Clinical
Interview(r=.70, p<.0001) (Beck & Gable, 2002). Probability analyses also revealed that
PDSS cutoff scores were derived to assure high levels of sensitivity and reasonable levels
of specificity to minimize the risks of failing to detect depressed mothers (Beck & Gable,
2002). The cutoff score for the suicidal thoughts content score was designed so that any
score above the minimum possible score of five would be considered elevated, primarily
to ensure the detection of women showing any evidence whatsoever of suicidal thoughts
(Beck & Gable, 2002).
Procedures
During check-in with office staff, each woman received a packet of materials
which included an informational letter explaining the nature of the study (Appendix A), a
hand-out providing a comprehensive list of mental health referrals and resources
(Appendix B), and three questionnaires: a mood disorders questionnaires (Appendix C);
a demographics survey (Appendix D) and a postpartum depression screen (see Appendix
E). All measures were taken at a single point in time (the postpartum visit), and
participants completed the study materials during the standard wait time in the waiting
room, the doctor’s office, and the examination room. All survey materials were numbered
and there were no blank spaces requesting any information which could potentially
identify participants. Completed surveys were placed in a file at the physician’s office
until picked up by the researcher. Neither the physician’s office nor the researcher was
aware of the individual identities corresponding to the completed packets. Volunteers
were not reimbursed in any way for their participation.
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Chapter 3
Results
Statistical Analysis
The Statistical Program for the Social Sciences 13.0 (SPSS) was used to create a
database in which to enter participant information. The database was independently
checked for accuracy. Descriptive statistics, including means, standard deviations, and
frequency distributions were computed. The analysis also included Pearson productmoment coefficient of correlations computed between relevant variables, as well as the
computations of a hierarchical regression analysis. A significant level, alpha, was
selected at <.05 for all statistical tests. The following section includes results of these
statistical analyses.
Description of the Participants
The Postpartum Depression Screening Scale (PDSS) was used to yield a total
score reflecting the presence and severity of symptoms of postpartum depression as well
as seven subscales reflecting symptom content. The mean total score for the sample
(N=202) was 59.38 (S.D = 21.08), with scores ranging from 35 to 128. Although the
majority of the sample (60%) had total scores which reflected a normal level of
adjustment (score of 59 or below), 24% had scores reflecting significant symptoms of
postpartum depression (score of 60-79) and 17% screened positively for major
postpartum depression (score of 80 or above).
An analysis of the symptom content scores revealed significant elevations for
those participants with a positive screen for postpartum depression in the areas of
sleeping/eating disturbances, anxiety/insecurity, emotional lability, mental confusion, and
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suicidal thoughts. The participants with significant symptoms of PPD but not a positive
screen did not, on average, show significant elevations in any of the symptom content
areas. See Table 7 for a comparison of symptom content scores between participants in
each of the three levels for total score (normal, significant symptoms, and positive
screen).
Table 7
Symptom Content Profile (N=202)

Range of Total Scores
________________________________________________________________________
Normal
Significant Symptoms
+ Screen
(n=121)
(n=46)
(n=35)______
Mean

S.D.

Mean

S.D

Mean

S.D.

Sleeping/Eating
Disturbance

7.05

2.42

10.8

3.58

14.26*

3.81

Anxiety/Insecurity

7.66

2.15

11.57

1.89

15.46*

2.48

Emotional Lability

7.33

2.29

11.61

2.53

17.26* 2.70

Mental Confusion

6.13

1.67

10.80

2.00

15.43* 2.90

Loss of Self

5.75

1.16

9.76

1.62

12.77

3.28

Guilt/Shame

5.93

1.53

9.57

1.87

12.43

4.48

Suicidal Thoughts

5.07

.56

6.00

1.79

SYMPTOM
CONTENT

7.69*

3.56

TOTAL SCORE
44.90
7.38
70.11
5.28
95.34 12.79
________________________________________________________________________
*indicates an elevated score.
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Correlational Analyses
The primary hypothesis of the study proposed using a one-way analysis of
variance (ANOVA) to compare the mean PPD scores of three groups of women (N=150;
n=50 for all groups): those who discontinued medication during pregnancy; those who
either continued or restarted medication during pregnancy; and a control group of women
not taking medication at or prior to conception. However, 9 months of data collection did
not yield enough women in the two medication groups (n=11 and n=17) to achieve
statistical power and was, therefore, not a testable analysis. In lieu of this analysis, a new
variable, medication status, was correlated with PPD, hypothesizing a negative
relationship (variable 9).
The second hypothesis contended that there would be a positive correlation
between PPD and longevity of medication among the subgroup of women who
discontinued medication during pregnancy (n=11). The results showed a negative but not
significant correlation between these two variables (r=-.340, p=.306). This suggests that,
contrary to the research hypothesis, postpartum depression decreases as length of time on
medication increases among this subgroup of medication discontinuers.
As the third hypothesis postulated, there were significant correlations between
total scores on the PDSS and selected variables, with N=202 for all correlations. There
was a significant positive correlation between the first variable, pregnancy mood, and
PPD (r=.391, p=.000). This finding shows that postpartum depression tends to increase as
depression in pregnancy increases, suggesting a relationship between prenatal depression
and postpartum depression. This constitutes a significant but weak/moderate
relationship.
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Next, there was a significantly positive correlation between the second variable,
child care stress, and PPD (r=.394, p=.000), suggesting that as stress related to caring for
one’s baby increases, postpartum depression also increases. The relationship between
these two variables is significant but weak/moderate. A significant negative correlation
was found between the third variable, emotional support, and PPD (r=-.385, p=.000); this
finding suggests that as emotional support increases, postpartum depression decreases.
The relationship between these two variables is significant, although weak/moderate.
Next, a significantly negative correlation was found between the fourth variable,
instrumental support, and PPD (r=-.385, p=.000), suggesting that as instrumental support
increases, postpartum depression decreases. The relationship between these two variables
is weak to moderate but significant. There was also a significantly negative correlation
found between the fifth variable, marital satisfaction and PPD (r=-.343, p=.000). This
finding suggests that as marital satisfaction increases, postpartum depression decreases
and also represents a significant, yet weak/moderate, relationship.
Variable 6, history of depression (treatment and/or symptoms), had
a significantly positive correlation with PPD (r=.222, p=.002), and this finding suggests
that individuals with a history of depression tend to have higher postpartum depression
scores. The relationship between these two variables is significant but weak. Similarly, a
significantly positive correlation was found between variable 7, baby temperament, and
PPD (r=.292, p=.000), suggesting that postpartum depression increases as a baby’s
temperament becomes increasingly more difficult. Although significant, the relationship
between these variables is weak.

62
Variable 8 (birth experience) had a significantly positive relationship with PPD
(r=.216, p=.002), suggesting that postpartum depression increases when difficult birth
experience increases. The relationship between these variables is significant but weak.
Finally, a significantly negative correlation was found between the ninth variable,
medication status (stopped medication, stayed on medication, not on medication at
conception), and PPD (r=-.220, p=.002). Theses findings suggest that PPD increases as
discontinuation of anti-depressant medication during pregnancy increases. The
relationship between these variables is significant but weak.
Regression Analysis
A hierarchical linear regression was performed to determine to what degree, if
any, each variable could explain the unique variance in postpartum depression scores at
six weeks postpartum. All variables were postulated to predict postpartum depression,
and the order of entry for the regression was pregnancy mood, care stress, emotional
support, and instrumental support, and marital satisfaction, history of depression, baby
temperament, birth experience, and medication status.
Child care stress (16%), pregnancy mood (9%), emotional support (5%), and
marital satisfaction (1%) accounted for 31.3% of the combined variability in postpartum
depression scores. In the first step, child care stress alone accounted for 16% of the
variance in postpartum depression scores (r=.394, R-square=.156, F (1,200) = 36.82,
p=.000). Next, pregnancy mood was entered into the equation to test its predictive role
above and beyond the effect of care stress. Pregnancy mood accounted for an additional
9% of the variance in postpartum depression scores (r=.499, R-square=.249, F (2, 199)
=33.06, p=.000). In the third step, emotional support was entered into the equation,
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accounting for an additional 5% of the variance in postpartum depression scores (r=.545,
R-square=.297, F (3, 198) = 27.92, p=.000). In the final step, marital satisfaction was
added to the equation, accounting only for an additional one percent of the variance in
postpartum depression scores (r=.559, R-square=.313, F (4, 197) =22.42, p=.000).
Instrumental support, history of depression, baby temperament, birth experience, and
medication status did not contribute significantly to the prediction of postpartum
depression. Please see Table 8 for a summary of the above information.
Table 8
Summary of Regression (N=202)
Dependent Variable: Postpartum Depression
Step

R

R²

AdjR²

F

SigF

R²Ch

FCh

SigCh

B

Sig

1

.394 .156 .151 36.83 .000

.156

36.83

.000

.394

.000

2

.499 .249 .242

33.06 .000

.094

24.90

.000

.315

.000

3

.545 .297 .287

27.92 .000

.048

13.50

.000

-.235

.000

4

.559

.015

4.44

.036

-.145

.036

.313 .299 22.42

.000

Predictors: (Constant), Care Stress
Predictors: (Constant), Care Stress, Pregnancy Mood
Predictors: (Constant), Care Stress, Pregnancy Mood, Emotional Support
Predictors: (Constant), Care Stress, Pregnancy Mood, Emotional Support, Marital Satisfaction
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Chapter 4
Discussion
This study examined the relationship between postpartum depression and several
variables in a sample of 202 women screened at the routine postpartum visit. The primary
purpose of the study was to determine the relationship between the discontinuation of
anti-depressant medication during pregnancy and the development of postpartum
depression. A history of depression is one of the most salient risk factors associated with
an onset of PPD, and approximately 12 million women in the United States experience a
clinical depression each year, most frequently during the child-bearing years (NIMH,
1999). Furthermore, anti-depressants have become increasingly standard in the treatment
of depression, with one study finding that anti-depressants represented the most
frequently prescribed medications to women during visits to physician offices and
hospital outpatient departments (Burt and Bernstein, 2003). The study intended to expand
the literature on postpartum depression to include medication discontinuation as a
potentially additional risk factor. The relationship between medication discontinuation
and mood has been fairly well studied in pregnancy (Einarson et al., 2001; Marcus et al.,
2005) but not in the postpartum.
The study originally intended to test its primary hypothesis using a one-way
analysis of variance in order to compare the means of three groups of women: those who
discontinued medication during pregnancy, those who stayed on medication during
pregnancy, and a control group who did not take medication prior to or during pregnancy.
However, nine months of data collection did not yield enough women in the two
medication groups [discontinuers (n=11) and continuers (n=17)] to achieve statistical
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power and was, therefore, not a testable analysis. In lieu of this analysis, the study used a
correlational analysis of the variable “medication status” (stopped medication, stayed on
medication, not on medication at or prior to conception) to determine its relationship with
postpartum depression.
Based on research linking long-term use of anti-depressants with tolerance and
relapse (Fava, 1999; Fava, 2003; Massou et al., 1997; Young et al., 1995; Zanardi et al.,
2001), the study also hypothesized a positive relationship between PPD and length of
time on medication among the subgroup of women who discontinued anti-depressants
during pregnancy. This finding was not substantiated, and the results showed a negative
and not significant relationship between PPD and length of time on medication among
those who discontinued medication. It is noteworthy that this sub-sample of subjects was
extremely small (n=11). One possible explanation for these findings is that those women
taking medication for a shorter duration may have been at increased risk for PPD if
medication discontinuation occurred prematurely and thus before a complete recovery
from symptoms. Similarly, those women taking medication for a longer duration may
have been in remission and may not have experienced a recurrence of symptoms by the
six week postpartum check-up.
The findings indicate a significantly positive correlation between PPD and
pregnancy mood. Although the relationship was weak/moderate, it still suggests that
symptoms of PPD increase as prenatal depression increases. Stated another way, women
who experience depression during pregnancy seem to be at an increased risk for
postpartum depression. Several biological, psychological, or social factors may
contribute to depression in pregnancy and the link between prenatal depression and PPD
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has been clearly established in the literature (Gotlib et al., 1991; Honey et al., 2003;
O’Hara et al., 1982; O’Hara et al., 1991; Righetti-Veltema et al., 1998). This study
corroborates the relationship between PPD and prenatal depression.
Results also showed a significantly positive correlation between PPD and child
care stress. Although weak to moderate, the relationship still suggests that symptoms of
PPD tend to worsen when women experience caring for their babies as being stressful.
Child care stress can result from a plethora of factors and may be precipitated by infantrelated stressors (i.e. neonatal complications, health problems, difficult temperament, and
poor orientation) and/or factors related to the mother’s physical, psychological, and/or
social state. This study provides additional support for a relationship between PPD and
child care stress which has been well-founded in the literature (Costa et al., 2000; Davis
et al., 2003; Edbor et al., 2000; Hopkins et al., 1987; O’Brien et al., 1999; Sutter-Dally et
al., 2003; Wood et al., 2004).
Significant but weak/moderate negative correlations were found between PPD
and emotional suppo rt, instrumental support, and marital satisfaction, suggesting that
symptoms of PPD tend to increase as support and marital satisfaction decrease. Although
fairly self-explanatory, emotional support may refer to feeling loved, nurtured, and cared
for by a spouse/partner and/or by extended family, friends, and/or community.
Instrumental support refers to more concrete forms of help with household chores and
baby care which can be received from a variety of sources (spouse, family/community,
hired help, etc...). Marital satisfaction refers to the degree of satisfaction with one’s
marriage; this may refer to situational stress related to inadequate spousal support
(emotional and/or instrumental) during the newborn adjustment period or to the existence
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of a more pervasive sense of dissatisfaction either prior to or during pregnancy. This
study provides additional support for the relationship between PPD and these variables.
The significantly positive relationship between PPD and a history of depression,
which included women with a history of symptoms who may or may not have received
treatment, was less robust than expected. The fact that the vast majority of the sample
(68%; N=202)) reported no history of depression offers one possible explanation for the
weak relationship between these variables. Risk factors other than a history of depression
may have been more salient with regard to the 40% of women in the sample (N=202)
who endorsed symptoms of PPD. The fact that 40% (N=202) of the women in this
sample had symptoms of PPD suggests that there were other more salient risk factors
related to the PPD.
The significant but weak positive correlation found between PPD and baby
temperament suggests that PPD tends to increase as the baby’s temperament becomes
more difficult. Difficult baby temperament refers to infants who cry frequently, react
negatively to new situations, and have irregular and unpredictable daily routines
(Santrock, 1983; Thomas & Chess, 1987). Although Whiffen & Gotlib (1989) found
evidence that two month old babies of depressed mothers were emotionally and
cognitively different from babies of non-depressed mothers, the authors could not
ascertain whether or not these differences were the result of actual infant disposition or of
infant response to being exposed to a depressed mother. In other words, this particular
study illuminated the challenge inherent in determining whether or not difficult infant
temperament is a cause or an effect of maternal depression. Cognitive distortions of
depressed mothers may also contribute to a less than accurate perception of infant
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temperament (Whiffen & Gotlib, 1989), further confounding the issue. It is beyond the
scope of this study to make these distinctions about self-reports of temperament;
however, the relationship between difficult baby temperament and PPD has corroborated
existing research.
The results also found a significantly positive, albeit weak, relationship between
birth experience and PPD, suggesting that symptoms of PPD increase when the birth
experience is reported as difficult. Difficult birth experience may be associated with pain,
medical complications, and/or personal/emotional complications and this may have some
connection with the type of delivery that occurs. Research has substantiated a relationship
between PPD and delivery by caesarean (Boyce & Todd, 1992; Edwards, Porter, & Stein
(1994). A study comparing planned versus emergency caesarean (Koo et al., 2003)
suggests that the salient factor has to do with the unanticipated nature of the emergency
rather than the surgical procedure alone. It is possible that a woman may report a difficult
birth experience when her actual experience does not meet her expectations, regardless of
type of delivery.
A significant but weak relationship was found between medication status and
PPD, suggesting a link between discontinuation of anti-depressant medication in
pregnancy and symptoms of PPD. Previous research has found a relationship between
medication discontinuation and depressed mood in pregnancy and, as already reported in
this study, a link between prenatal depression and PPD has been well-established. Giving
birth and adjusting to the new mother role represents a significant stressor for all women,
especially those already predisposed to depression (Riecher-Rossler & Fallahpour, 2003).
The findings of this study suggest that women who stop taking anti-depressants during
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pregnancy may be placing themselves at increased risk as they approach the postpartum,
a time of heightened vulnerability. The limited number of women in the sample who
discontinued medication (n=11) may, in part, explain the weak relationship between these
variables.
The four predictor variables (child care stress, pregnancy mood, emotional
support, and marital satisfaction), accounting for 31.3% of the variance in PPD scores,
provide additional support to the existing literature on predictor variables. A substantial
body of research has identified these variables as predictive of PPD (Beck, 2001; Leung,
2002, Logsdon, 2001; Whiffen, 1988). Predictors can be used to ascertain a woman’s risk
for developing PPD. Unless a woman has experienced child care stress with previous
births, assessment of this variable prior to delivery will be difficult and may instead be
assessed by evaluating a woman’s history of adjusting to new and potentially demanding
situations. Assessment of mood in pregnancy can be fairly easy to assess if obstetrical
staff are willing to implement formal depression screening throughout the prenatal
period. Emotional suppo rt and marital satisfaction can also be assessed prenatally with
the caveat that these variables are subject to change during the postpartum period,
especially if, for example, a husband or partner’s behavior falls short of the new mother’s
expectations.
Summary of Results
In summary, significantly positive correlations were found between PPD and
pregnancy mood, child care stress, history of depression, baby temperament and, birth
experience. Significantly negative correlations were found between PPD and emotional
support, instrumental support, marital satisfaction, and medication status. Hierarchical
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multiple regression indicated that child care stress and pregnancy mood predicted a
significant amount of the variance in postpartum depression, and emotional support and
marital satisfaction accounted for a significant yet smaller portion of the variance in PPD
scores. A negative but not significant correlation was found between PPD and length of
time on medication for the subgroup of women who discontinued medication during
pregnancy.
The results of this study supported all hypotheses except the prediction of a
positive correlation between PPD and length of time on medication for the subgroup of
medication discontinuers. Most results were less robust than anticipated, most likely
because the majority of the sample (60%) did not have any symptoms of PPD, and only
17% endorsed symptoms indicative of a positive screen for postpartum depression.
Interpretation of Results
Seventeen percent of the participants in this sample had symptoms indicative of
major postpartum depression, and this falls within the 10 to 20% range of new mothers
estimated to become afflicted with PPD (NMHA, 2003). Women in this range tended to
endorse symptoms related to disturbances in eating and/or sleeping, feelings of anxiety
and/or insecurity, feeling of emotional instability, feelings of mental confusion, and
suicidal thoughts. It is noteworthy that an additional 24% of the sample endorsed
significant symptoms of PPD, indicating the potential presence of a minor depression.
The fact that a substantial proportion of women ( 41% ;N=202) in the current study were
experiencing symptoms beyond the baby blues indicates that many of these women are
indeed suffering, identifying a need for additional evaluation and possible treatment.
As is the case with many obstetrical practices, this particular office did not
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conduct any formal screening for postpartum depression at the time of the study.
Therefore a physician would become aware of a woman’ s symptoms only if she
discussed them during the exam, and this is less likely, considering the embarrassment
and guilt frequently associated with this disorder. The current study provides further
evidence that screening does increase detection, most likely because women are more
comfortable recording their symptoms as an initial step, before discussing these
symptoms with their physicians. Further, recognizing some of their own symptoms in
writing may provide some relief by normalizing the disorder to some degree.
The study sample represented a fairly homogenous group in demographic terms.
Most of the subjects in the sample were white, married, middle class women who were
well-educated. The results may have been confounded by the preponderance of married
subjects, especially considering the potentially protective value that social support and
marital satisfaction has on postpartum mood. A larger proportion of single parents in the
study may have been associated with an increase in postpartum depression scores,
especially in the absence of other protective factors (such as social support from sources
other than a spouse). The high proportion of middle class women in the study sample
may also have confounded the results of the study, especially considering the relationship
found between PPD and low socioeconomic status (Beck, 2001; Kuo et al., 2004; Seguin,
Potvin, St.-Denis & Loiselle, 1999). There may have been an increase in postpartum
depression scores if the sample had been represented by a higher proportion of low
socioeconomic status mothers.
Half of the sample were first-time mothers, and it is noteworthy that the average
age of the sample was 30 years old, suggesting the postponement of motherhood
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presumably to fulfill other roles. The relationship between age and PPD has not been
well-studied and was not hypothesized by the current study. A sample with a higher
average age may have been at greater risk for PPD, especially for career-oriented
primiparous mothers for whom motherhood represents a drastic lifestyle change.
However, experience with motherhood may serve as a protective factor for multiparous
mothers in this higher age group. By comparison, the lifestyle change may not be as
salient a factor in a sample of mothers with a lower average age; yet, lack of emotional
maturity and inadequate planning for parenthood may be a factor which increases risk for
younger mothers. Regardless of age, it is possible that the stigma resulting from
unrealistic expectations about motherhood is a more salient risk factor for primiparous
women experiencing motherhood for the first time. A larger proportion of primiparous
mothers in the current study may have been associated with higher PPD scores. In terms
of the proportion of women taking anti-depressants proximate to pregnancy (13%;
N=202), the current study is, however, representative based on a similar proportion found
in the Marcus et al. (2005) study (11%; N=3500).
Despite the demographic homogeneity of the sample, the results provide
additional support for correlates of PPD that had already been studied in the literature,
suggesting that PPD is a disorder that afflicts women in general, without respect to their
demographic characteristics. According to Beck’s (2001) meta-analysis, prenatal
depression, child care stress, social support, marital relationship, history of depression,
and infant temperament represented six of 13 predictors for PPD and had moderate effect
sizes. This study certainly upheld the positive relationship between PPD and mood in
pregnancy, even though the study did not glean the reasons for prenatal depression in the
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sample. The study also upheld the positive relationship between PPD and child care
stress, suggesting that the women in this sample experienced more depression when they
experienced child care as a stressor, regardless of whether or not the stress was a
reflection of something externally or internally produced.
The negative relationships between PPD and both emotional and instrumental
support that the study upheld, suggest that an absence of support, whether perceived or
real, can put women at risk in the postpartum. Although separate constructs, the influence
that emotional and instrumental support potentially have on one another may have
impacted the results of the correlational analyses. For example, a woman who asks her
husband to perform more hands-on duties (housework, child care) may subsequently feel
more emotionally supported by him as well. Likewise, if a woman perceives the
emotional support of friends and family, she may be more inclined to ask for assistance
with more concrete duties. The negative relationship found between marital relationship
and PPD may also be related to the support constructs, because a poo r marital
relationship could either precede or follow inadequate support. Bernazzani et al. (1997)
found that the correlation between difficult relationship and prenatal depression had an
indirect effect on PPD, and Hock et al. (1996) found a significant correlation between
symptoms of PPD at 9 months and a decline in marital satisfaction between the prenatal
and postnatal period.
Other correlates upheld by this study include difficult infant temperament and
difficult birth experience. Women with more difficult babies, regardless of whether or not
the babies were actually more difficult or were reacting to the stress of being cared for by
a depressed mother, had higher levels of depression. Likewise, women who reported
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having a more difficult birth experience, regardless of the reasons, tended to experience
higher levels of depression. The construct of difficult birth experience in this study
represents difficulty as a result of pain, medical complications, and/or personal
complications, without respect to type of delivery. Therefore a woman’s mental and
physical state, as well as her pain threshold, most likely contributed to her assessment of
her own birth experience. Based on research correlating PPD and an emergency c-section
(Koo et al., 2003), it is possible that the relationship between PPD and a difficult birth
experience may have been more robust if the number of women reporting an emergency
c-section in the current study (n=26) had been larger.
The findings related to the variable, medication status, were significant but not as
robust as anticipated, suggesting that medication discontinuation poses an additional risk
factor for symptoms of PPD. As previously discussed, analysis of the primary hypothesis
was modified due to lack of participants in each of the two medication groups of the
study, despite procedure modifications. Data collection at the additional sites yielded
only 2 additional surveys, and it is possible that women were less forthcoming with
information when they self-selected, based on anti-depressant use. It is also possible that,
even among the 200 women who were included in the study regardless of medication
status, there was some hesitation to share information about anti-depressant use,
especially if this information was not shared with their obstetricians. Fears of being
stigmatized have impeded women from speaking up about their depression, especially in
the postpartum (Tam et al., 2000).
It is also possible that the demographic homogeneity of the sample also reflected
a homogeneity regarding beliefs about depression and its treatment. Despite substantial
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increases in the rate of anti-depressant treatment (Stafford et al., 2001), it is possible that
the vast majority of this particular sample of women did not experience or seek medical
treatment for depression shortly before or during pregnancy. The most salient possibility
suggests that obtaining enough subjects to study the relationship between medication
status and PPD requires screening a larger number of participants. The current study’s
proportion of women taking medication proximate to pregnancy (13%; N=202) parallels
the Marcus et al. (2005) study in which only 11% of 3500 participants had taken
medication close to conception.
The fact that most of the findings in the current study were less robust than
expected suggests that certain moderator variables may have served a protective role for
some potentially at-risk women. Dimensions of psychological hardiness, described as a
personality style characterized by the components of commitment, control, and challenge,
have been shown to moderate the relationship between stress and depression (Oman &
Oman, 2003; Pengilly & Dowd, 2000; Rhodewalt & Zone, 1989; Santrock, 1983). It is
possible that, in the current study, women with psychological hardiness were more adept
at managing any stress associated with the postpartum and therefore more resilient to
symptoms of depression. Similarly, women having better developed coping skills,
whether or not they are learned or inherent dimensions of personality, tend to manage
stress more productively. Effective coping may include the use of proactive problemsolving strategies aimed at altering the source of stress or the use of emotion-focused
strategies, such as cognitive restructuring, recreational activities, humor, religion, and
spirituality aimed at reducing emotional distress (Carver, Scheier & Weintraub, 1989;
Matheson & Anisman, 2003). In the current study, it is possible that better developed
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coping skills may have moderated the impact of stress and served to protect some women
from experiencing symptoms of PPD. This may be especially salient considering that the
majority of the sample is well-educated, a factor which can impact learned coping skills.
A po sitive attributional style frequently associated with optimism represents
another potential moderator variable in the current study. Individuals having a positive
attributional style tend to credit themselves for positive experiences in their lives and
have hope that the future will bring more positive experiences in all facets of their lives
(Scott, 2006). Likewise, they attribute negative experiences to external factors and
perceive these experiences as isolated incidents which are not representative of
themselves or the future. Positive thinking has been associated with higher self-esteem
and is potentially a depression-buffer (Hull & Mendolia, 1991; Lightsey, 1994) and a
moderating factor which may have enabled some participants in the current study to
manage PPD-related stressors effectively and to experience healthier outcomes.
Other factors potentially impacting the outcome of the current study concerns
multiparous women who may have experienced PPD following a previous birth. This
subgroup of women may have approached the current birth more realistically and
implemented a plan of action in an attempt to effect a more positive outcome. Whether or
not a women’s role either as a stay-at-home or as a working mother met her pre-birth
expectations may also be a factor related to PPD. A woman having to return to work due
to financial constraints may become depressed if she expected (and hoped) to stay home
and care for her baby. Likewise, a woman needing to stay home to care for a baby with
health problems may become depressed, especially if she had expected to return to work.
Exposure to other life stressors (such as an ill family member, death of a loved one, or
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unemployment of a spouse) during the postpartum period may also increase a women’s
vulnerability to depression and may have been a factor affecting the outcome of the
current study. An unplanned pregnancy represents another potential factor which may
have mediated the relationship between PPD and other variables identified by the current
study.
Clinical Implications
Estimates indicate that approximately 50% of symptomatic women do not seek
treatment for PPD (Chaudron, 2003; Lane et al., 1997), usually out of embarrassment and
fears of being stigmatized. Yet, 40% of the women in the current study endorsed some
degree of symptoms of PPD, with 17% screening positive for a major disorder. It is
difficult to know if women are more inclined to be forthcoming on a pen and paper
measure than they would be if they are forced to discuss symptoms of PPD with their
physicians, who may lack the knowledge and/or self-efficacy needed to put patients at
ease. If, as some research suggests, screening increases the detection of PPD (Chaudron
et al., 2004; Freeman et al., 2005), then this creates opportunities for clinical
psychologists to develop relationships with obstetrical and pediatric practices to conduct
or oversee screening in exchange for referrals to further evaluate and treat symptomatic
women. This arrangement benefits providers of medical/mental health care and patients
alike. An understanding of the risk factors supported in this study will help clinicians
utilize a biopsychosocial approach to assess, diagnosis, and treat women both prenatally
and in the postpartum. This is critical because the risk factors identified in this study are
multi-faceted in nature, reflecting biological, psychological, and social aspects of
individuals’ lives.
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Results of this study indicate that clinical psychologists would benefit from
having knowledge of the risks and benefits of anti-depressant discontinuation during
pregnancy. During the time period in which the study took place, the FDA required
manufacturers to add warning labels regarding risks associated with third trimester
exposure (Moses-Kolko et al., 2005) and gave Paxil a higher risk pregnancy rating.
Clearly, the trend over the past few years has been to increase the level of caution
regarding anti-depressant use during pregnancy, and this will likely exacerbate the
medication cessation dilemma for women who have benefited from treatment with antidepressants.
With this knowledge, clinical psychologists can play a significant role by assisting
clients who face the medication-during-pregnancy dilemma with problem-solving and
risk-benefit strategies applied during therapy sessions. Clinicians can begin this process
by having discussions with all child-bearing age therapy clients who have been
prescribed anti-depressant medication, regardless of whether or not they are pregnant or
even contemplating pregnancy. Preliminarily increasing women’s awareness and
understanding of the realities associated with medication continuation/discontinuation in
pregnancy may help them plan more effectively for the future by enabling them to make
more informed choices.
Psychologists treating clients who decide to discontinue medication during
pregnancy can treat any symptoms of depression that may arise throughout the pregnancy
and use psychoeducation to help clients anticipate problems in the postpartum. Multiple
sessions of cognitive behavioral therapy would likely be a good substitute for medication,
based on studies demonstrating its effectiveness when used alone or in combination with
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other treatments (Appleby et al., 1997; Chabrol et al., 2002; Cooper et al., 2003; Honey et
al., 2002; Prendergast & Austin, 2001). These sessions can focus on increasing clients’
coping skills to enable them to manage potential postpartum stressors more effectively.
Current coping skills can be assessed in order to identify strengths and deficits.
Dependent upon the areas of deficit, new coping skills can include problem-solving
strategies aimed at changing some aspect of the stressor or self-care strategies aimed at
reducing emotional distress.
Clinical psychologists, especially those working in behavioral medicine settings,
can be proactive in the prevention of PPD by educating medical staff, as well as patients
and their families about the risk factors associated with PPD, including the psychosocial
and neuroendocrine changes which are unique to the postpartum period (DSM-IV-TR,
2000). In addition to obstetrical and pediatric providers of patients having private
insurance, it is critical to disseminate information to providers of underserved populations
who frequently receive federal or state-funded health care benefits. These include
agencies such as Planned Parenthood as well as federally funded clinics serving both
women and children. Informed physicians and other medical staff that come into contact
with postpartum women can not only better educate patients but can also increase their
ability to understand and potentially detect symptoms. Incorporating presentations about
PPD at venues where medical staff receive continuing education credits represents an
effective way to disseminate information to large audiences; these are venues such as
conferences, seminars, and hospital grand rounds. Developing separate prenatal classes
on PPD or incorporating a greater depth of information into already existing childbirth
classes represent a few ways to increase patient awareness. Providing pamphlets and
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other written materials in the offices of obstetricians and pediatricians represent another.
A government-sponsored program similar to the one launched by the state of New Jersey
under Acting Governor Richard J. Codey is an extremely effective way to reach a large
audience. However, these programs are costly and stand a better chance of being
implemented when someone in public office expresses a personal interest, as was the case
in New Jersey.
Increasing awareness and knowledge of PPD not only increases the detection of
PPD but also helps to create an environment that normalizes the disorder and encourages
women to discuss their symptoms without fear of stigmatization. It is unfortunate that
the cases of PPD to which many women are exposed are the very rare and extreme cases
of psychosis reported by the media. These cases frequently have tragic endings involving
infanticide and/or suicide; women who equate PPD with these extreme cases may
continue to suffer silently based on erroneous beliefs that less severe, non-life-threatening
symptoms do not constitute PPD. Opportunities abound for clinical psychologists to
intervene by assisting women and their families either to avert or to cope with a
potentially debilitating disorder which can have deleterious effects on women, children,
families, and society as a whole.
Limitations of the Study
The cross-sectional design of the study limits the ability to determine the cause
and effect relationships among the variables. The fact that 99% of the study participants
were patients of a primarily suburban, central Pennsylvania obstetrical practice limits the
ability to generalize the results to other practices on the basis of geographical and
philosophical differences which may impact decision-making in the practices. The
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demographic homogeneity of the sample also makes it difficult to generalize the results
to populations that are more diverse in terms of race, education, marital status, and
socioeconomic class. Because screening took place at a single point in time, limitations
exist in the ability to generalize results to measurements taken at time periods other than
the 6 week postpartum check-up. The study cannot be generalized to the subgroup of
women who schedule, but never receive postpartum follow-up care.
Limitations also exist regarding the method by which participants were screened.
Because all the questionnaires relied on self-reports, individuals may have had a tendency
to respond in a socially desirable manner. This is especially salient with regards to the
postpartum period during which women have demonstrated a reluctance to discuss
symptoms based on beliefs that motherhood should be a joyful and fulfilling time.
Individual responses on the PDSS may have reflected attempts to appear less depressed
and therefore happier in their mother role than they actually were. Furthermore,
individual responses on the demographic survey may have also reflected social
desirability, especially regarding sensitive topics such as marital satisfaction and
depression-related issues. Despite the anonymity of the surveys, it is possible that some
women were reluctant to share information about their mental health.
Another threat to the study’s validity includes the reliance on voluntary
participation in the study. In other words, the fact that certain individuals may have opted
not to participate may have confounded the results of the study, and this may have been
even more salient after the procedures were changed to include only those women who
had a recent history of anti-depressant use. Again, despite the anonymity of the surveys,
women may have been reluctant to respond when the inclusion criteria was more limited,
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especially if social desirability was a factor. It is noteworthy that the addition of a third
data collection site utilizing the new procedures did not yield any new participants,
despite a month-long attempt to recruit approximately 30 women when they checked in
for their postpartum appointment.
Another limitation of the study concerns the fact that the only measure used to
assess postpartum depression (the PDSS) is merely a screening instrument and not a
diagnostic tool. The measure is intended to serve as a “gatekeeper” to identify women at
risk for PPD, with the presumption that these women will be subsequently referred for an
additional evaluation (Beck & Gable, 2002). In other words, collateral data in the form of
a clinical interview both with patient and family must augment the screen to complete the
assessment and make appropriate referrals to mental health professionals if necessary.
Finally, testing the primary hypothesis of the study was limited by the inability to
perform the intended statistical analysis due to a lack of participants who had taken
medication immediately prior to pregnancy. This may have been prevented had the study
continued for longer than 9 months. However, considering the aforementioned issues
related to social desirability and self-selection, it is possible that it would have taken
months to obtain the necessary number of surveys to perform the intended analysis.
Another possibility would have been to add more data collection sites and to include sites
with a larger number of postpartum patients. Further, even among the small group of
subjects taking SSRI anti-depressants at pregnancy, there may have been differences in
the results based on they type of medication taken. Although it is beyond the scope of this
study to examine individual medications, a women’s unique physiology combined with
the different chemical composition of each of the SSRI medications may have affected
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mood symptoms related to discontinuation or continuation during pregnancy and
subsequently in the postpartum.
Future Research
Future research of anti-depressant discontinuation in pregnancy should screen a
larger group of more demographically diverse postpartum women in order to obtain
enough subjects to conduct a more powerful statistical analysis. The medication cessation
dilemma for pregnant women or those contemplating pregnancy is likely to continue,
given the availability and effectiveness of SSRI anti-depressants, combined with the
recent FDA warnings regarding fetal exposure to these medications. Both continuation
and discontinuation of medication in pregnancy poses risks to the fetus, the former in
terms of fetal exposure to medication in utero and the latter in terms of potential fetal
exposure to maternal depression. Even if women endure symptoms of depression during
pregnancy, the postpartum represents a period of additional risk as a result of the
psychosocial and physiological changes that occur. Continued research of this issue is
critical to ascertain the degree to which medication cessation in pregnancy serves as an
additional risk factor for postpartum depression. Research should also focus on the nature
of the risk-benefit analysis undertaken by these women and the extent to which they
sought consultation both from family members and professionals alike. It is important to
understand how much information women have at their disposal when they must make
this difficult choice.
Because of the validity constraints imposed by screening at a single point in time
and because symptoms of PPD can develop anytime within the first postpartum year,
future researchers should consider screening women at various postpartum intervals (i.e.
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6 weeks, 3 months, 6 months, 12 months). Although requiring a greater investment in
time, identifying medication status and screening women for depression in pregnancy
with a follow-up in the postpartum may provide researchers with a more comprehensive
understanding of this issue. Previous research (Marcus et al., 2005) studying the
relationship between medication status and mood in pregnancy can be expanded to the
postpartum.
Future research of mood in the postpartum should continue to use the PDSS
because it was created specifically to measure postpartum depression but this research
may also use other more general measures of depression, especially if convergent validity
is a concern. Adding a brief clinical interview may also help to glean more information
about a particular woman’s symptom profile and may also encourage women to discuss
their symptoms honestly and to seek help if necessary.
In an effort to increase prevention and assessment of PPD, future researchers
should continue to assess the knowledge and awareness of medical professionals who
come into contact with postpartum women, namely obstetricians and pediatricians; they
should also determine the degree to which screening programs are already in place.
Previous research has identified a lack of knowledge by these professionals (Dietrich et
al., 2003; Stevens & Diehl, 2003; Wiley et al., 2004), opening the door for future
research to focus on the implementation of training programs to ascertain their impact on
the detection and treatment of PPD. Generally speaking, the underlying goal of any
research concerning postpartum depression should be to augment the literature on the
prevention, assessment, and/or treatment of this potentially debilitating disorder in order
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to increase societal knowledge and enable women to enjoy this special time with their
babies.
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Appendix A
Dear Study Participant:
My name is Maria Murphy, and I am doctoral candidate at the Philadelphia College of
Osteopathic Medicine (PCOM). I am conducting a study and requesting your help to
understand the relationship between postpartum depression (PPD) and certain risk
factors. You are being asked to participate in this study because you have recently had a
baby and have an appointment with your doctor today for your postpartum check-up. By
agreeing to participate, you will be asked to complete and return 3 questionnaires. This
will take approximately 20 to 30 minutes of your time. You will also be provided a list of
mental health referrals to assist you in seeking help should you be experiencing any
symptoms of postpartum depression now or in the future.
While you may not benefit directly from this study, other people in the future may benefit
from what the researchers learn from this study. Also, if you are experiencing any
emotional distress, you will benefit by being provided with a list of referrals and
information about some symptoms of PPD. Although there are no known risks
associated with your participation in this study, exploring emotional issues and questions
about depression may cause you to experience discomfort and/or distress. It is expected
that this will be minimal to none. You will not receive any payment for being in this
study but your participation is gratefully appreciated.
Your participation in this study is completely voluntary and you may refuse to be in the
study with no risk of penalty to you. You may choose to discontinue participation in the
study at any time. There will be no penalty or consequence for failing to complete the
survey materials.
Your responses to the questionnaire and survey will remain completely confidential and
will not identify you by name. Therefore, we ask that you refrain from putting your name
on any of the questionnaires you will be returning to us. After your participation, the
researcher will not have access to any information which could potentially identify you.
If you have any further questions about the research, you can contact the Principal
Investigator (Dr. Barbara Golden) at the following address: PCOM, Psychology
Department, 4170 City Avenue, Philadelphia, PA 19131-1694; (215) 871-6495. If you
want to know more about Dr. Golden’s background or the rights of research subjects, you
can call Dr. Frederick Goldstein, Chairperson, PCOM Institutional Review Board at
(215) 871-6859.
Thank you in advance for your participation in this study.
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Appendix B
Referral List
Shortly after the birth of a baby, most women experience feelings of sadness
which usually pass after 2 or 3 days. For many women, these symptoms persist and
result in postpartum depression (PPD). Symptoms of PPD are similar to those for major
depression and may include
• persistent feelings of sadness or emptiness
• frequent crying
• loss of pleasure for previously enjoyed activities
• feeling irritable or angry
• having either a poor or an excessive appetite
• having trouble falling asleep, waking up too early, or sleeping too much
• feeling restless and agitated or having little energy
• extreme fatigue
• feeling anxious
• feeling guilty or worthless
• having trouble concentrating
• feeling unable or unwilling to care for your baby
• feeling hopeless or thinking your children would be better off without you
• worrying excessively about your baby’s health
• intrusive thoughts about harming yourself or your baby.
If you are experiencing any of the above symptoms, please know that you are NOT
ALONE and that HELP IS AVAILABLE. The following includes a list of mental
health treatment providers who can offer assistance. (You may also contact your
insurance carrier for a list of covered providers). Thank you for your participation.
IF YOU ARE HAVING THOUGHTS OF HARMING YOURSELF OR YOUR
BABY, PLEASE SEEK HELP IMMEDIATELY
Crisis Intervention:
Cumberland County:
Carlisle Area: 717-243-6005
Shippensburg Area: 717-532-8049
Camp Hill Area: 717-763-2222
Duncannon Area: 717-834-3326
Dauphin County:
717-232-7511 or 888-596-4447
Support Groups/Resources:
PinnacleHealth WomanCare Resource Center @ 717-782-2727 or
www.pinnaclehealth.org.
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Psychotherapists:
Holy Spirit, Behavioral Health Services, Camp Hill, 717-763-2219
Pauline Wallin, Ph.D., Camp Hill, 717-761-1814
Jeff Verrechio, M.S., Camp Hill, 717-761-5301
PinnacleHealth Psychological Associates, Harrisburg, 717-231-8360
Susan Gillius, M.S., Lemoyne, 717-730-8555
Cheryl Shope, M.S., Lemoyne 717-730-8555
Psychiatrists:
John Mira, M.D., Camp Hill, 717-763-1191
J.K. Moola, M.D., Camp Hill, 717-761-1325
Other:

Depression After Delivery, Inc.
91 East Somerset Street
Raritan, NJ 08869
1-800-944-4773
http://www.depressionafterdelivery.com
Postpartum Support International
927 N. Kellogg Avenue
Santa Barbara, CA 93111
voice (805) 967-7636
fax (805) 967-0608
www.postpartum.net

Books (many of these books are available in paperback and can be purchased used from
Amazon.com):
*Shouldn’t I be Happy? Emotional Problems of Pregnant and Postpartum Women by
Shaila Misri, M.D.
*Mothering the New Mother: Woman’s Feelings and Needs After Childbirth- A Support
and Resource Guide by Sally Placksin
*Conquering Postpartum Depression by Ronald Rosenberg, M.D.
*Behind the Smile: My Journey Out of Postpartum Depression by Marie Osmond.
*A Mouthful of Air by Amy Koppelman
*The Cradle Will Fall by Michele Remington
*Beyond the Blues: A Guide to Understanding and Treating Prenatal and Postpartum
Depression by Shoshana S. Bennett
*This Isn’t What I Expected: Overcoming Postpartum Depression by Karen Kleinman
and Valerie Raskin
*Postpartum Depression: Every Women’s Guide to Diagnosis, Treatment, and
Prevention by Sharon Roan
*Overcoming Postpartum Depression & Anxiety by Linda Sebastian
*Postpartum Survival Guide by Anne Dunnewold and Diane G. Sanford
*A Mother’s Tears: Understanding the Mood Swings that Follow Childbirth by Arlene
Huysman
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Appendix C
MOOD DISORDERS QUESTIONNAIRE
1. Has there ever been a period of time (at least TWO weeks) when you have
been bothered by any of the following problems?
Not at all

Several More than
days
half the days

Nearly
every
day

a .Little interest or pleasure in doing things
b. Feeling down, depressed, or hopeless
c. Trouble falling or staying asleep, or sleeping
too much.
d. Feeling tired or having little energy.
e. Poor appetite or overeating.
f. Feeling bad about yourself, or that you are a
failure, or have let yourself or your family
down.
g. Trouble concentrating on things, such as
reading the newspaper or watching T.V.
h. Moving or speaking so slowly that other
people could have noticed? Or the opposite –
being so fidgety or restless that you have been
moving around a lot more than usual.
i. Thought that you would be better off dead or of
hurting yourself in some way.

2. Has there ever been a period of time (at least ONE week) when any of the
following occurred at the same time?
Yes No

a. You felt much more self-confident than usual.
b. You got much less sleep than usual and found you didn’t really miss
it.
c. You were much more talkative or spoke faster than usual.
d. Thoughts raced through your head or you couldn’t slow your mind down.
e. You were so easily distracted by things around you that you had trouble
concentrating or staying on track.
f. You had much more energy than usual and tried to accomplish many more
things than usual.
g. You did things that were usual for you or that others might have thought were
excessive, foolish, or risky (such as buying sprees, risky sexual activity, or
foolish business investments).

3. If you checked off any problems in #1 or #2, how much of a problem did any
of these cause you (like being unable to work; having family, money, or legal
troubles, getting into arguments/fights?)
No problem

Minor problem

Moderate Problem

Serious problem
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The following section contains some general questions.
1. Your Age: ______
2. What is the highest education you have earned?
[] less than high school
[] high school graduate
[] some college
[] 4-year college degree.
[] graduate degree or more
3. What is your race or ethnic group?
[] White
[]Asian
[]Black or African American
[]American Indian or Alaskan Native
[]Hispanic or Latino
[]Native Hawaiian or other Pacific Islander
[]Other (Please specify)___________________________________________
4. What is your marital status?
[]Single
[]Divorced
[]Married
[]Separated
[]Partnered
[]Widowed
[]Other (please specify)_________________________________________
5. If married or partnered, please describe your level of satisfaction with
your current relationship?
[] Very Satisfied
[] Satisfied
[] Neutral
[] Unsatisfied
[] Very Unsatisfied
6. What is you household’s current gross annual income?
[]<$20,000
[]$75,001-$100,000
[]$20,000-40,000
[] over $100,000
[]$40,001-75,000
7. Please list any significant health problems or conditions you have
experienced, either before or during your pregnancy (such as thyroid
problems, heart problems, cancer, diabetes, gestational diabetes, etc…)
_______________________________________________________________
_______________________________________________________________
.
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8. Please list any medications you have been taking to treat any significant
medical conditions_______________________________________________
______________________________________________________________.
9. How many times have you been pregnant?_______
10. How many biological children have you had?________

The following questions pertain to your current pregnancy and birth
experience.
11. . What type of delivery did you have?
[] Vaginal (not-induced)
[] Induced vaginal after natural labor faltered
[] Planned caesarean section
[] Emergency caesarean section
12. Did you have ______a single birth OR ______multiple births?
13. What was the date of your baby’s birth?__________________________.
14. How would you describe your pregnancy?
[] problem-free
[] difficult due to medical complications.
[] difficult due to personal/emotional complications
[] on bed-rest.
[] other (please specify_______________________________________).
15. How would you describe your birth experience?
[] problem-free
[] difficult due to pain
[] difficult due to medical complications
[] difficult due to personal/emotional complications
[] difficult due to medical and personal/emotional complications
[] other (please specify________________________________________).
16. What, if any, types of pain-relieving medication did you receive during
your labor and delivery?________________________________________.
17. Was your baby born prematurely (less than 36 weeks gestation)?
[] Yes
[]No
18. What was your baby’s birthweight? __________
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19. Does your baby have any health or developmental problems which have
been identified since birth?
[] Yes (please explain)___________________________________________
[] No
20. How would you describe your baby’s temperament on a scale from 1 to 5,
with “1” being extremely easy-going and “5” being extremely difficult?
[] 1
[] 2
[] 3
[] 4
[] 5
21. Was this a planned pregnancy?

[]Yes

[]No

22. Were you treated for infertility prior to the pregnancy? [] Yes []No
23. How would you rate the level of emotional support you currently
receive to help you care for your baby?
[] an abundance of support
[] adequate support
[] some support but not adequate
[] no support
24 .How would you rate the level of financial support/assistance you
currently receive to help you provide for your baby?
[] an abundance of support
[] adequate support
[] some support but not adequate
[] no support
25. How would you rate the level of instrumental support (i.e. help with daily
feeding and changing, provide babysitting) you currently receive?
[] an abundance of support
[] adequate support
[] some support but not adequate
[] no support
26. How would you describe your mood during this pregnancy on a scale of
1 to 5, (“1” being not depressed at all and “5” being extremely
depressed)?
[] 1
[] 2
[] 3
[] 4
[] 5
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27 . How are you feeding your baby?
[] breast.
[] bottle (formula).
[] combination (breast milk and formula).
28. How stressful has it been for you to provide daily care for your baby?
[] Extremely stressful.
[] Moderately stressful.
[] Mildly stressful.
[] Not stressful at all.
29. If you were being treated for depression when you became pregnant OR
immediately prior to pregnancy (either shortly before or during the time
you were trying to conceive), what type of treatment did you receive?
[] Anti-depressant medication
[] Therapy or counseling
[] Medication and counseling
[] Other (please specify________________________________________)
[] N/A
30. If you were being treated for depression with ANTI-DEPRESSANT
medication when you became pregnant OR immediately prior to
pregnancy (either shortly before or during the time you were trying to
conceive), which medication(s) were you taking?
[] N/A
[] Prozac or Prozac Weekly or Sarafem
(fluoxetine)
[] Zoloft (sertraline)
[] Celexa (citalopram)
[] Lexapro (escitalopram)
[] Luvox (fluvoxamine)
[] Paxil (paroxetine)
[] Effexor (venlafaxine)
[] Wellbutrin (buproprion
[] Remeron (mirtazapine)
[] Serzone (nefazodone)
[] Desyrel (trazodone)

[] Elavil (amitriptyline)
[] Anafranil (clomipramine)
[] Norpramin (desipramine)
[] Adapin or Sinequan (doxepin)
[] Tofranil (imipramine)
[] Aventyl or Pamelor(nortriptyline)
[] Vivactil (protriptyline)
[] Surmontil (trimipramine)
[] Nardil (phenelzine)
[] Parnate (tranylcypromine)
[] Other (please list_________
________________________).

31. For how long did you take the medication(s) listed in #30?
[] N/A
[] 0 to 9 months.
[] more than 9 months (please indicate actual time_________________).
[] other (please indicate____________________________________).
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32. In addition to the medications listed in #27, please indicate any other
medications that you also took for your mood.
[] N/A
[] Eskalith or Lithonate (lithium)
[] Zyprexa (olanzapine)
[] Symbyax (olanzapine/fluoxetine)
[] Risperdal (risperidone)
[] Tegretol (carbamzepine)
[] Abilify (aripiprazole)
[] Trileptal (oxcarbazepine)
[] Geodon (ziprasidone)
[] Depakote (divalproex)
[] Stelazine (trifluoperazine)
[] Neurontin (gabapentin)
[] Haldol (haloperidol)
[] Lamictal (lamotrigine)
[] Navane (thiothizene)
[] Topamax (topiramate)
[] Seroquel (mesoridazine)
[] Moban (molindone)
[] Clozaril (clozapine)
[] Loxitane (loxapine)
[] Thorazine (chlorpromazine)
[] Other (please list___________________ [] Prolixin (fluphenazine)
_________________________________).
33. Did you continue to take anti-depressants for the duration of your
pregnancy?
[] N/A
[] Yes
[] No
34. Did you switch to a different anti-depressant during your pregnancy?
[] N/A
[] Yes (please specify)___________________________________
[] No
35. If you decided to stop taking anti-depressants while you were trying to
conceive or when you discovered you were pregnant, please indicate
your reasons (check all that apply):
[] N/A
[] Didn’t want to risk harm to unborn baby.
[] Didn’t think I needed them anymore.
[] Followed doctor’s recommendations.
[] Experienced unwanted side effects.
[] Other (please specify)_______________________________________..
36. Did you either begin taking or restart anti-depressant medication at any
time during your pregnancy due to an increase in symptoms of
depression?
[] Yes
[] No
[] N/A
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37. What were your doctor’s recommendations about taking anti-depressants
during pregnancy?
[] advised me to stop taking medication
[] advised me to continue taking medication
[] presented information but left decision up to me
[] had no recommendations
[] other (please specify________________________________________).
[] N/A
38.What treatments are you currently receiving for depression?
[] Anti-depressant medication (name of medication__________________)
[] Therapy/counseling.
[] Medication and therapy/counseling.
[] N/A
39. What were your doctor’s recommendations about taking anti-depressants
while breast-feeding?
[] advised me to stop taking medication.
[] advised me to continue taking medication
[] presented information but left decision up to me
[] made no recommendations
[] other (please specify)_____________________________________.
40. Did you switch from breast or combination feeding to all bottle-feeding
because you began taking anti-depressants?
[] Yes
[] No
[] N/A

The following questions concern any HISTORY of depressive symptoms
you may have had prior to this pregnancy.
41. Please indicate any treatment you’ve ever received for depression at any
time prior to your most recent pregnancy and birth (check all that
apply).
[] N/A because I have no history of depressive symptoms
[] I’ve never received treatment despite having symptoms
[] medication (please state name of medication_____________________)
[] counseling/therapy
[] other (please specify)_____________________________________.
42. If you have had prior births, did you ever experience symptoms of
depression (such as a loss of pleasure for things you previously enjoyed,
depressed mood, anxiety, sleeping or eating disturbances, poor concentration,
etc..) within a few weeks or months after giving birth?
[]Yes
[]No
[] N/A
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AppendixE

Below is a list of statements describing how a mother may be feeling after the birth of her baby. Please indicate how much you agree
or disagree with each statement. In compleUng the Questionnaire, please circle the answer that best describes how you have felt over
the past 2 weeks. Read each item carefully. Then circle the number that best fits your answer. Please give only one response for each
statement, using the following scale:
4
5
3
2
Agree
Strongly
N-either A.gree
Strongly
Disagree
Agree
nor Disagree
Disagree
If you wish to change your response, completely mark through your first response with an "X."
Then circle the response that best fits your new choice.

·During the past 2 weeks,
...... 2

.. 3 ..... .4 ..... 5.

1.

1,

had trouble sleeping even when my baby was asleep.

..... 2 ..... 3 .... 4 ..... 5.

2.

j

got anxious over even the littlest things that concerned my baby.

...... 2.. ..3 .... 4 .....5.

3.

i felt like my emotions were on a roller coaster.

3 ..... .4 ..... 5.

4.

i felt like I was losing my mind .

...... 2 ..... 3 ...... 4..... 5.

S.

I was afraid that I would never be my normal self again .

6.

1felt like I was not the mother I wanted to be.

I.

I nave thought that death seemed like the only way out of thiS living nightmare.

..... 2 .

. 2 ..... 3 ..... 4 ..... 5 ..

...... 2 ..... 3

. .4 ..... 5 ..

Stap here if }'DU were asked to complete !J{li,/ the Short Form.
.. . 3

..... 2

.. .4 . . ... 5

8.

I lost my appetite.
I felt really overwhelmed .

.... .2

... 3 .... .4 . . ... 5

9.

...... 2

... 3 ... .. .4 . .... 5 .

10.

.2

... 3

.4 ..... 5

11. I could not concentrate on anything .

.. .2

.3

.. .4 ..... 5

12. I felt as though I had become a stranger to myself.

.. .3

.. .4 ..... 5

13.

1

.... .2

1

..

I was scared that I would never be happy again .

I felt like so many mothers were better than me.

.. 2

... 3

.. .4 .... 5

14.

[started thinking that I would be better off dead.

...... 2

... 3

.. .4 ...... 5 ..

15.

I woke up on my own in the middle of the night and had trouble getting back to sleep.

16.

I felt Jlke I was jumping out of my skin .

1 .... 2

... 3 ..... .4 ..... 5.

1 ... .2 ....3 ..... .4
1 .... 2
1 .. ... 2

.3

.. 5

17. I cried ala! for no real reason .

4 ..... 5

18.

... 3 ..... 4 . . ... 5

19. ! did not know who I was anymore .

. 2 .. .. 3 .... .4 .... 5 .
..... 2 ... .. 3 .... .4

.. 20.

.5 ..

21.

1...... 2 ...... 3 .... .4 ....5 ..
1 .... 2 ....3 .... .4 ..... 5.
...... 2
.2

.. .. 2

..... 2
..... 2

... 22.
....... ...

.. ... 2 ..

I wanted to hurt myself.
I tossed and tumed for a long time at night trying to fall asleep.

23. ! felt all alone .

... 3

. . .4 .. ... 5 .. ... ...

. 3 ..... .4
..... 3

.. ...

.5.

. .4 ..... 5 . .

25. I had a difficult time making even a simple decision .

.. ..

26. I felt like I was not normal.

..... ...

27. I felt like I had to hide what I was thinking or feeling toward the baby.

.....

28. I felt that my baby would be better off without me.

.. . 3 .... .4 .....5

29.

. 3 ... .. .4 .. ... 5. . .. .. .. 30.

..... .2 .. .. 3 .. .. .4 ..... 5 . . ... ... ... 3!.

...... 2 ..

I felt guilty because I could not feel as much love for my baby as ! should .

... 3 .. ... 4 .....5 ..... .. ... 24. I have been very irritable .

1 .... 2 .... 3 ..... .4 ..... 5
1 .... 2

I thought 1was going crazy.

3 ..... 4 .....5 . . .. ...
.. 3 ... 4

"

I knew I should eat but I could not.
! felt like t had
j

to keep moving or pacing .

felt full of anger ready to explode .

32. I had difficulty focusing on a task .

.... 5 ..... . .. ... 33. I did not feel real

.2

..3 ... 4 ...... 5

.... .2

... 3 .. .. .4 . .. .. 5

........ ..

34 . i felt like a failure as a mother.

35. I just wanted to leave this world .

